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 Structured Abstract 
 
Background: Drug use in youth is associated with multiple negative health and social 
consequences. Even infrequent use increases one’s risk of serious adverse events due to an 
increase in risk-taking behaviors while intoxicated or impaired. Primary care could play a role in 
helping to prevent and reduce drug use in children and adolescents. 
 
Purpose: To systematically review the evidence on the benefits and harms of primary care–
relevant interventions designed to reduce illicit drug use or the nonmedical use of prescription 
drugs in children and adolescents.  
 
Methods: We searched PubMed, PsycINFO, and the Cochrane Collaboration Registry of 
Controlled Trials to identify relevant literature published between January 1992 and June 4, 2013 
and MEDLINE through August 31, 2013. We also examined the references from other relevant 
reviews and included studies. Two investigators independently reviewed all titles/abstracts and 
full-text articles against a set of predetermined inclusion and quality criteria. One reviewer 
abstracted data into a standard evidence table and a second reviewer checked the data for 
completeness and accuracy. We qualitatively synthesized the results for the three Key Questions 
and grouped the included studies by intervention type (primary care–based vs. primary care–
relevant computer-based interventions conducted outside of primary care).  
 
Results: We included six studies reported in seven publications. Four of the six trials examined 
the effect of the intervention on a health outcome. One study found no effects of either a 
therapist-led or computer-based brief intervention on marijuana use consequences or driving 
under the influence of marijuana. Only one of the three computer-based interventions that 
reported depression outcomes found greater improvement in the intervention group compared 
with the control group at 6 months only. All six trials reported a drug use outcome. Four of the 
five studies assessing self-reported marijuana use found statistically significant differences in 
favor of the intervention group compared with the control group. All three computer-based trials 
also reported differences in nonmedical prescription drug use occasions. Individual studies 
reported additional substance use outcomes with mixed results.  
 
Conclusions: There is inadequate evidence on the benefits of primary care–relevant behavioral 
interventions in reducing self-reported illicit and pharmaceutical drug use in adolescents.  
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 Chapter 1. Introduction 
 
Scope and Purpose 
 
In 2008, the U.S. Preventive Services Task Force (USPSTF) concluded that there was 
insufficient evidence to recommend for or against screening adolescents, adults, and pregnant 
women for illicit drug use. This recommendation was based on a staged evidence review1 of the 
literature published between 1994 and April 2006 and a 2008 supplemental assessment of 
screening instruments done on behalf of the USPSTF.2 The staged review only included research 
related to screening or treatment for marijuana, cocaine, or opioids and included evidence for 
children and adolescents, adults, and pregnant women. In contrast, the current systematic review 
focuses specifically on: 1) behavioral interventions that are considered feasible for primary care; 
2) the primary prevention and reduction of all illicit drugs, including the nonmedical use of 
prescription drugs; and 3) children and adolescents age 18 years and younger only who do not 
meet criteria for substance abuse or dependence. The objective of this review is to systematically 
review evidence for the benefits and harms of primary care–relevant behavioral interventions 
designed to reduce illicit drug use or the nonmedical use of prescription drugs in children and 
adolescents. 
 
Condition Definition 
 
Substance use typically refers to substances that affect mental processes (e.g., cognition, affect) 
when ingested, inhaled, injected, or taken through other administration routes. These substances 
have psychoactive properties and can include licit and illicit substances, such as alcohol; 
tobacco; marijuana; prescription drugs, including opioids and morphine derivatives; depressants; 
and stimulants. In this review, we focus on illicit drug use and the nonmedical use of prescription 
and over-the-counter drugs. We did not review the evidence related to alcohol, tobacco, and 
nonpsychoactive drugs (e.g., anabolic steroids or laxatives). Nonmedical use (also known as 
“extramedical use”) refers to using a prescription or over-the-counter drug in ways other than 
prescribed (i.e., more frequently or for a longer duration) or by people other than the prescribed 
individual. Individuals generally use these substances to “get high” or for other unapproved 
indications.  
 
An individual’s substance use can range from abstinence to dependency or addiction (Table 1). 
In this review, we are specifically interested in interventions that aim to prevent (i.e., primary 
prevention prior to any use) or reduce drug use in children and adolescents who have 
experimented with drug use, have limited drug use, or have problematic/harmful drug use. We 
did not review the evidence on interventions designed to reduce drug use in children and 
adolescents who are diagnosed with substance abuse or substance dependence according to the 
Diagnostic and Statistical Manual of Mental Disorders (4th edition) or similar criteria.3 The 
distinction between problematic use and abuse is somewhat ambiguous clinically. Problematic 
use is often associated with use of the substance in high-risk situations, such as driving a car, or 
is associated with problems such as a school suspension. Diagnosed abuse, on the other hand, 
reflects recurrent problems associated with use that interferes with functioning.  
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 Prevalence 
 
There are three main U.S. surveillance surveys that track trends in the prevalence of alcohol, 
tobacco, and other drug use in children and adolescents: 1) the annual National Survey of Drug 
Use and Health in children age 12 years and older, 2) the annual Monitoring the Future Study of 
students in grades 8, 10, and 12, and 3) the biannual Youth Risk Behavior Survey of students in 
grades 9 through 12. Substance use is typically reported as lifetime (or ever) use, use during the 
past year, use during the previous 30 days (often referred to as “current” use), daily use, or use 
over some other defined period of time (e.g., 14 or 90 days). Rates of current substance use over 
the past 5 years are similar in all three surveillance systems.4  
 
According to the 2012 National Survey of Drug Use and Health, 9.5 percent of adolescents ages 
12 to 17 years reported current (past month) illicit drug use—a rate that has remained steady 
since 2009.4 Marijuana and prescription psychotherapeutics (including pain relievers) are the 
most commonly used drugs among children and adolescents (Table 2). Nearly 7.2 percent of 12- 
to 17-year-olds reported current use of marijuana and an estimated 5.0 percent used marijuana 
for the first time within the past year.4 Consequences of prescription drugs used for nonmedical 
purposes are a quickly growing epidemic in the United States. These drugs include opioid pain 
relievers, central nervous system depressants, and stimulants and are the number one cause of 
unintentional drug overdose.5 In 2012, 2.8 percent of 12- to 17-year-olds reported using a 
prescription drug for nonmedical reasons; 2.2 percent of those individuals reported this to be 
opioid pain relievers.4  
 
To put the rates of drug use in context with the use of other substances, in 2012 the rate of 
current alcohol use in youths ages 12 to 17 years was 12.9 percent and current cigarette use in 
this group was 6.6 percent. Illicit drug use was approximately 15 times higher in young persons 
who smoked cigarettes and drank alcohol during the past month (61.1%) than in those who 
neither smoked cigarettes nor drank alcohol during the past month (4.0%).4  
 
Drug-use patterns differ between sex and race or ethnic groups. Males, for example, are more 
likely than females to have ever used or be current users of all types of drugs, except for ever use 
of inhalants.4,6,7 Black and Hispanic students, on the other hand, have a higher rate of having 
ever used marijuana than white students, with lifetime prevalence reported at 43.0, 42.1, and 37.9 
percent, respectively. Cocaine, inhalant, heroin, and methamphetamine use was higher in 
Hispanic students than white and black students. The use of prescription drugs for nonmedical 
purposes, on the other hand, was higher in white (22.9%) students than black (14.7%) or 
Hispanic (19.4%) students. More white (9.3%) and Hispanic (9.1%) students report current use 
of hallucinogens than black (3.3%) students.7 There are also slight differences in illicit drug use 
by the type of county individuals reside in (i.e., urban or rural). Drug use is more common in 
urban and large metropolitan settings than any other areas.4 
 
In 2012, approximately 7,900 individuals age 12 years and older initiated drugs every day, 
representing an estimated 2.9 million new users per year. Most first-time illicit drug users 
(55.1%) were younger than age 18 years. The average age at drug use initiation in 2012 was 17 
years in 12- to 49-year-olds. In 2012, the majority (65.6%) of those who used illicit drugs for the 
first time during the past 12 months used marijuana as their first drug. The nonmedical use of 
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 psychotherapeutics was reported by 26.0 percent of new initiates as their first drug used 
(includes 17.0% with pain relievers, 4.1% with tranquilizers, 3.6% with stimulants, and 1.3% 
with sedatives). Inhalants were reported as the first drug used by 6.3 percent of new users, and 
hallucinogens by 2.0 percent of new initiates in 2012.4 
 
The rate of illicit drug dependence or abuse in young persons ages 12 to 17 years in 2012 was 4.0 
percent, which is a 1.6 percent decline from 2002, when 5.6 percent of 12- to 17-year-olds were 
diagnosed with substance dependence or abuse. The rate of substance dependence and abuse 
(alcohol and drugs) was the same for males and females in 2012 (6.1%). Individuals who initiate 
marijuana use at younger ages (i.e., age 14 years or younger) are more likely to develop drug 
dependence or abuse as adults than those who initiate marijuana use after age 18 years.8 
 
Burden 
 
Drug use is associated with multiple negative health, social, and economic consequences. In 
2010, for example, 64 percent of all deaths in young persons ages 1 to 24 years in the United 
States resulted from three causes: unintentional injuries, including motor vehicle accidents 
(38%); homicide (13%); and suicide (12%).9 The use of alcohol and other drugs is the primary 
health risk behavior that contributes to these leading causes of morbidity and mortality in 
adolescents and young adults.7 While experimentation with alcohol or marijuana are often 
incorrectly regarded as developmentally normative behaviors in adolescents, even infrequent use 
increases an individual’s risk of serious adverse events due to an increase in risk-taking 
behaviors while intoxicated or impaired. Risky behaviors often do not occur in isolation. Indeed, 
alcohol, tobacco, and other drug use are commonly associated with other risky behaviors, such as 
driving under the influence, early and unsafe sexual activity, and interpersonal violence.  
 
In 2009, the Drug Abuse Warning Network estimated that approximately 55,306 emergency 
department (ED) visits by adolescents ages 12 to 17 years involved illicit drugs (alone or in 
combination with alcohol and/or prescription drugs).10 Marijuana (182.2 visits per 100,000 
individuals), cocaine (21.4 visits), ecstasy (17.5 visits) and stimulants (15.0 visits) were the most 
commonly reported illicit drugs that led to an ED visit by children and adolescents. The 
nonmedical use of prescription drugs was involved in over 66,000 ED visits by children and 
adolescents, with pain relievers (e.g., opioids) being the most commonly reported substance. 
 
National tracking systems of fatal poisonings capture deaths due to drug use. These systems 
report that the majority of poisoning deaths are due to illicit and licit drugs (nine out of 10 
poisoning deaths for all ages are caused by drugs). From 1999 to 2008, the drug poisoning death 
rate for the U.S. population ages 15 to 24 years increased from 3.2 per 100,000 to 8.2 per 
100,000.11 Unintentional poisoning deaths (due to drugs and other substances) increased by 91 
percent from 2000 to 2009 for those ages 15 to 19 years and by 36 percent for those ages 10 to 
14 years.12 
 
Drug use can also have deleterious effects on educational achievement and attainment. Cross-
sectional and longitudinal studies show that students who dropped out of school or were at risk 
for dropping out of school had higher rates of marijuana use than students who remained in 
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 school or graduated. Studies that examined the relationship between other nonmarijuana drug use 
and dropping out of school report mixed results, with some showing that drug use and dropping 
out of high school are related, while others indicate that the association varies by race/ethnicity 
and is confounded by other factors.13 
 
Risk and Protective Factors 
 
Research has identified multiple risk and protective factors that influence adolescent substance 
use. Risk factors include substance use by family members (specifically parents and siblings), 
poor parental supervision and household disruption, low academic performance or aspirations, 
decreased participation in school activities, poor relationships with teachers, untreated attention 
deficit hyperactivity disorder, and perceived peer acceptance of substance use and actual use 
among peers. Protective factors include parents who set clear rules and enforce them, parents 
who regularly talk with their children about the dangers of substance use, having a parent in 
recovery, having a positive school climate and a positive sense of community, involvement in 
religious or other community programs, and having adequate opportunities in the community for 
prosocial involvement.14-17  
 
While not everyone who uses tobacco or alcohol will progress to illicit drug use, tobacco or 
alcohol use often precedes marijuana and other illicit drug use and the use of one substance can 
be a marker for the use of others.18 A recent study found that alcohol use is the first step toward 
using tobacco and illicit drugs.19 Marijuana use in adolescents has been linked to illicit drug 
abuse and dependency and using more types of illicit drugs.20 
 
Behavioral Interventions in Primary Care 
 
Preventing and reducing drug use in adolescents is a national priority. Healthy People 2020 
substance abuse objectives include increasing the proportion of high school seniors who have 
never used illicit drugs, decreasing the proportion of young persons who use marijuana for the 
first time, and decreasing the proportion of adolescents who report using marijuana and 
nonmedical use of prescription drugs or inhalants.21  
 
To reduce the health burden associated with substance use and substance use disorders, the 
Substance Abuse and Mental Health Services Administration (SAMHSA) recommends that 
universal screening for substance use, brief intervention, and/or referral to treatment (the SBIRT 
model) become a part of routine health care.22 SBIRT is an early intervention approach that 
targets individuals with nondependent substance use and provides strategies for intervention 
before the need for more extensive or specialized treatment. Brief interventions, in particular, are 
well-suited for use in primary care. This approach is a precursor to interventions that focus on 
specialized treatment of individuals with more severe substance use or those who have met the 
criteria for a diagnosis of a substance use disorder (i.e., abuse or dependence). Therefore, brief or 
early intervention is a proactive approach that is initiated by the health care provider rather than 
the patient.  
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 Among children and adolescents, the term “brief intervention” includes a broad range of clinical 
activities intended to prevent, delay, or reduce substance use in individuals with varying 
experience with substances. These activities include positive feedback to nonusers as primary 
prevention; brief advice as a form of secondary prevention for those at low risk for abuse; or an 
intervention using motivational techniques directed at reducing use, associated high-risk 
behaviors, and/or getting a patient to accept a referral to treatment if they are at high risk for or 
abusing drugs. The SBIRT model for children and adolescents is slightly different than the 
model applied for adults, in which the focus is on brief, motivational interventions for those 
identified “at risk” for abuse or dependence. Because any substance use can negatively affect the 
health of children and adolescents, brief interventions are designed to provide positive 
reinforcement, brief advice, or brief motivational interventions for youth at all stages of use. 
According to SAMHSA, a brief intervention usually involves one to five sessions of 5 minutes to 
1 hour in duration. These interventions can be delivered via face-to-face sessions, written self-
help materials, a computer intervention, or telephone counseling. 
 
The American Academy of Pediatrics has developed specific guidelines through Bright Futures 
for screening for and counseling about alcohol and illicit substance use. This group specifically 
recommends that pediatricians provide substance abuse (i.e., alcohol, tobacco, and drug) 
education and screening to adolescents during routine clinical care, incorporating the SBIRT 
guidelines designed by SAMHSA.14,23 Furthermore, it advises that brief counseling and in-office 
followup may be sufficient if patients report substance use without associated problems and there 
have been no adverse consequences of substance use. More intense intervention and referral for 
treatment are indicated, however, when children or adolescents are identified as having 
experienced adverse events related to their substance use (e.g., injuries associated with acute 
intoxication, trouble with the law, truancy, decline in school performance, or deterioration in 
physical or mental health), are regularly using drugs (including the use of more drugs and on a 
more frequent basis), or are using drugs to “feel normal.”24  
 
Current Clinical Practice in the United States 
 
Few primary care physicians or their adolescent patients report specifically discussing substance 
use or drug use. Less than 50 percent of pediatricians report screening their adolescent patients 
for substance use or abuse in their general pediatric visits.25 In one survey of adolescent patients, 
only 35 percent reported discussing substance use with their physicians, although 65 percent 
wanted to talk about substance use.26 Difficulties with discussing the issues (e.g., parent present 
in the examination room), insufficient time, level of physician preparedness, and belief that 
treatment is not effective are reported as common barriers for not discussing substance use with 
children and adolescents.27,28  
 
Previous USPSTF Recommendation 
 
In 2008, the USPSTF concluded that the current evidence was insufficient to assess the balance 
of benefits and harms of screening adolescents, adults, and pregnant women for illicit drug use (I 
statement).  
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 Chapter 2. Methods 
 
Key Questions and Analytic Framework 
 
With input from the USPSTF, we developed an Analytic Framework (Figure 1) and three Key 
Questions (KQs) using the USPSTF’s methods29 to guide the literature search, data abstraction, 
and data synthesis for this topic. The proposed Analytic Framework and KQs were posted on the 
USPSTF’s Web site for public comment for 4 weeks. We revised the Analytic Framework and 
KQs based on public comment, with final approval by the USPSTF. We examined the following 
KQs: 
 
1. Do primary care behavioral counseling interventions for drug use, with or without referral, 
improve mortality, morbidity, and other health, social, and legal outcomes in children and 
adolescents? 
a. Do outcomes differ in subgroups (e.g., as defined by age, risk level, sex, race, ethnicity, 
or types of substances used)?  
b. What are elements of efficacious interventions?  
c. What criteria are used to identify children and adolescents for primary care drug use 
interventions?  
2. Do primary care behavioral counseling interventions for drug use, with or without referral, 
prevent drug use initiation in children and adolescents who do not currently use drugs or 
reduce drug use in children and adolescents who currently use drugs?  
a. Do outcomes differ in subgroups (e.g., as defined by age, risk level, sex, race, ethnicity, 
or types of substances used)?  
b. What are elements of efficacious interventions?  
c. What criteria are used to identify children and adolescents for primary care drug use 
interventions?  
3. What are the adverse events of primary care behavioral counseling drug use interventions? 
 
Data Sources and Searches 
 
In addition to reviewing the two trials specific to children and adolescents that were captured in 
the 2008 review,1 we searched MEDLINE, PubMed, PsycINFO, and the Cochrane Collaboration 
Registry of Controlled Trials for relevant publications through June 4, 2013 and MEDLINE 
through August 31, 2013 (Appendix A). Our searches were restricted to English-language 
publications published since January 1992. We chose this start date based on a 12-year decline in 
annual prevalence of adolescent illicit drug use from 1980 through 1992, with a sharp increase in 
1993.6 This shift is referred to as the “relapse phase” in the drug epidemic. We also examined the 
reference lists of six relevant published reviews or meta-analyses30-35 and all of our included 
studies to identify other studies for inclusion. We also conducted grey literature searches of 
government agencies (e.g., AHRQ, SAMHSA), professional organizations (e.g., American 
Academy of Pediatrics), and other organizations (e.g., University of Washington Alcohol and 
Drug Abuse Institute) that sponsor or publish relevant research for synthesized evidence 
published outside of peer-reviewed journals. In addition, we searched for potentially relevant 
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 ongoing or recently completed studies in children and adolescents through ClinicalTrials.gov 
(http://www.clinicaltrials.gov/), Current Controlled Trials (http://www.controlled-trials.com), 
Australian New Zealand Clinical Trials Registry (http://www.anzctr.org.au), and the World 
Health Organization’s International Clinical Trials Registry Platform 
(http://www.who.int/ictrp.en). We supplemented our searches with suggestions from experts and 
articles identified through news and table-of-contents alerts from sources such as ScienceDirect 
(Elsevier, Maryland Heights, MO), HighWire Press (Stanford University Libraries, Palo Alto, 
CA), and Pediatrics. 
 
We managed our literature search results using version 12.0 of Reference Manager® (Thompson 
Reuters, New York, NY), a bibliographic management software database. 
 
Study Selection 
 
Two investigators independently evaluated 2,253 abstracts for potential inclusion against 
prespecified eligibility criteria. Of these, we dually reviewed 144 full-text articles for possible 
inclusion in this review (Appendix A Figure 1). Full-text articles that were excluded are listed 
in Appendix B, including the specific reason for exclusion. We resolved reviewer discrepancies 
through discussion or consultation with the larger project team. Detailed inclusion and exclusion 
criteria are provided in Appendix A Table 1 and are discussed below.  
 
We included randomized, controlled trials (RCTs) or controlled (nonrandomized) clinical trials 
designed to prevent or reduce drug use in children and adolescents (no lower age restriction to 18 
years) published in English in or after 1992. We excluded studies conducted in treatment-seeking 
children or adolescents or those that were mandated or directly referred to substance abuse or 
dependence treatment via the juvenile justice system, social services, parents, or a similar referral 
system. We also excluded trials in which more than half of the sample was diagnosed with 
substance abuse or dependence or a drug use disorder. Included interventions targeted children or 
adolescents or their parents and were delivered individually or in small groups. We examined 
trials conducted in primary care or that were potentially feasible to conduct in primary care, with 
or without referral to specialty treatment services. This included interventions delivered 
exclusively through electronic media (e.g., Web-based, CD-ROMs) that were not linked to health 
care. We describe these trials collectively as “primary care–relevant.” We excluded trials 
evaluating the effects of detoxification or medically managed withdrawal, inpatient or residential 
treatment, and broad public health or policy interventions. Trials had to take place in a primary 
care setting or ED. Other settings were included, however, if the study was linked to primary 
care or health care (e.g., recruitment in clinics), such as research clinics/offices, community 
centers, or participants’ homes. We excluded interventions that took place in substance abuse 
treatment centers, schools, worksites, and other institutions, such as juvenile detention centers, as 
they were seen as not generalizable to primary care. Studies had to take place in “very high” 
developed countries as defined by the 2011 Human Development Index of the United Nations 
Development Programme. Included trials had control arms that offered minimal or no 
intervention or an attention-control arm. Trials were only eligible if they reported a health, 
social, legal, or drug use outcome or a harm of the intervention at least 6 months after the 
baseline assessment. Given the volatile nature of behaviors in youth, outcomes reported at less 
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 than 6 months may not be truly reflective of intervention effects. 
 
Quality Assessment and Data Abstraction 
 
We used predefined criteria developed by the USPSTF to assess the quality of all trials meeting 
our inclusion criteria.29 Two investigators independently assessed the quality, resulting in a 
rating of “good,” “fair,” or “poor” (see Appendix A Table 2 for quality criteria). We examined 
potential risks of bias, including randomization procedures and measurement procedures 
(including blinding and consistency between groups); comparability of the groups at baseline; 
overall and group-specific attrition; intervention fidelity and participant adherence; and the 
appropriateness of the statistical procedures, including methods for handling missing data. In 
general, a good-quality study employed valid randomization methods, including concealing 
treatment allocation, included comparable groups at baseline or appropriately adjusted for 
potential confounders in the analysis, had followup data on 90 percent or more of participants, 
and used reliable measures of drug use. Trials were rated as “poor” if attrition was greater than 
40 percent; attrition in the intervention and control groups differed by more than 20 percentage 
points; or there were other important flaws, such as noncomparable groups at baseline. Studies 
that reported 10 to 20 percent differential attrition were categorized as fair. We excluded poor-
quality studies from this review. We resolved differences in quality rating through discussion.  
 
After quality rating, we abstracted data from all included studies into a standard evidence table. 
One reviewer abstracted data from all good- and fair-quality studies and a second reviewer 
checked the abstracted data for accuracy. We collected the following information for each study, 
where available: study characteristics (e.g., setting), recruitment methods, and eligibility criteria; 
study population, including the number of participants included/randomized and demographic 
characteristics; intervention and control descriptions; followup rates; and outcomes.  
 
Data Synthesis and Analysis 
 
We summarized all included studies in narrative form and summary tables that detail the 
important features of the study populations, design, intervention, outcomes, and results. We 
reported the risk ratio and between-group differences that were reported by the included studies, 
where available. We identified too few trials and too much variability in a number of factors to 
conduct any pooled analysis. Instead, we conducted a qualitative analysis for all KQs and 
stratified the results into two groups based on the type of intervention: 1) primary care–based and 
2) computer-based. Primary care–based studies recruited directly from or were conducted in 
primary care clinics. Computer-based interventions only used electronic modes of intervention 
delivery (e.g., Web-based or CD-ROM) and were not conducted in primary care. We discuss the 
outcomes for the two groups separately. Within each group, we qualitatively explored patterns of 
association between group differences and the following factors: the type of intervention, the 
mode and duration of the intervention, and the substance or substances targeted.  
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 Expert Review and Public Comment 
 
A draft of the Analytic Framework, KQs, and inclusion/exclusion criteria was posted on the 
USPSTF’s Web site for public comment from January 15 to February 11, 2013. We received 
comments from 14 individuals, including eight individuals providing comments on behalf of 
their organization. All comments were reviewed and addressed as appropriate. A final research 
plan was posted on the USPSTF’s Web site on May 9, 2013. The full draft report was reviewed 
by experts and Federal partners from May 31 through June 14, 2013. We compiled and 
addressed (where appropriate) the comments received from invited reviewers. Additionally, a 
draft of the full report was posted on the USPSTF’s Web site from October 1 through October 
28, 2013. A few comments were received during this public comment period; there were no 
major changes made. All minor, editorial suggestions were addressed as appropriate. 
 
USPSTF Involvement 
 
We worked with four USPSTF liaisons at key points throughout this review, particularly when 
developing the Analytic Framework, KQs, and scope of the review. The USPSTF liaisons 
approved the final Analytic Framework, KQs, and inclusion/exclusion criteria after revisions 
reflecting the public comment period. AHRQ funded this review under a contract to support the 
work of the USPSTF. An AHRQ Medical Officer provided project oversight, reviewed the draft 
report, and assisted in the external review of the report.  
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 Chapter 3. Results 
 
Literature Search 
 
We identified six trials meeting our eligibility criteria that examined the effects of primary care–
relevant interventions designed to prevent or reduce drug use in children and adolescents. These 
trials were reported in seven publications.36-42 Of the 143 full-text articles that were reviewed, the 
most common reasons for exclusion included the setting (i.e., not linked to or feasible for 
primary care; k=45), population (i.e., age 18 years or older, treatment seeking, or diagnosed with 
substance abuse or dependence; k=26), and not reporting any relevant outcomes (k=19) 
(Appendix A Figure 1). 
 
We considered all of the included trials to be primary care–relevant because they were conducted 
in primary care or were judged to be feasible for primary care. Three of the studies were 
conducted in or recruited directly from primary care (i.e., “primary care–based”),38,39,42 while the 
other three studies all tested the same computer-based intervention that was considered 
potentially feasible for primary care.36,40,41 Only one of the studies exclusively targeted drug use 
behaviors (alcohol use was a secondary outcome).42 Among the others, three of the six studies 
targeted alcohol, tobacco, and drug use behaviors. The remaining two studies targeted alcohol 
and drug use behaviors only. None of the studies addressed long-term behavioral or health 
outcomes beyond 2 years. Table 3 and Table 4 present study and intervention characteristics of 
all of the included studies. 
 
Key Question 1. Do Primary Care Behavioral Counseling 
Interventions for Drug Use, With or Without Referral, Improve 
Mortality, Morbidity, and Other Health, Social, and Legal 
Outcomes in Children and Adolescents? 
 
Key Question 2. Do Primary Care Behavioral Counseling 
Interventions, With or Without Referral, Prevent Drug Use 
Initiation in Children and Adolescents Who Do Not Currently 
Use Drugs or Reduce Drug Use in Children and Adolescents 
Who Currently Use Drugs? 
 
Study Characteristics 
  
Primary Care–Based Interventions 
 
Three studies testing four active treatment arms were conducted in or recruited from primary 
care; they varied greatly in terms of their study population, intervention, outcomes, and quality 
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 (Tables 3 and 4).38,39,42 A fair-quality study conducted by Harris and colleagues published in 
2012 was a quasiexperimental design conducted in two sites—the United States and Czech 
Republic.38 The study’s primary aim was to evaluate the immediate (3-month) and long-term 
(12-month) effects of a primary care computer-facilitated screening and brief advice system on 
adolescent alcohol and marijuana use. Within the United States, the study was conducted at nine 
primary care offices in three New England states (n=2,106). In the Czech Republic, the study 
included 10 pediatric generalist offices in Prague (n=589). Each site implemented an identical 
protocol. The study included patients ages 12 to 18 years partaking in routine primary care. At 
baseline, 12.8 and 14.0 percent of adolescents in the United States and Czech Republic cohorts, 
respectively, reported any past marijuana use. Baseline reports of ever having used alcohol were 
higher in the Czech Republic cohort (59.7%) than the U.S. cohort (28.5%). The intervention 
began with a computer-based, self-administered screening tool that asked adolescents about their 
lifetime and past-12-month use of substances (i.e., alcohol, marijuana, and “anything else to get 
high”) followed by the CRAFFT (Car, Relax, Alone, Forget, Friends, Trouble) screening 
questions.43 Participants were shown their individual CRAFFT score and risk level (low, 
medium, or high) after completing the screening questionnaire. Participants were then invited to 
read 10 pages of scientific information and true-life stories about substance use on the computer 
screen. Adolescents spent 5 minutes on average with the screening and educational computer 
program. Based on the adolescent’s screening results, the provider was given a report that 
displayed their patient’s risk level and six to 10 talking points designed to prompt a 2- to 3-
minute brief advice discussion. This advice was tailored to advise the patient to “not start” or 
“stop” using substances, based on the adolescent’s responses to the screening questionnaire. 
Providers at both sites underwent training to standardize the intervention. Control participants 
received treatment as usual. Substance use was assessed using a modified timeline follow-back 
interview that recorded frequency of use of multiple substances. The timeline follow-back 
interview has been found to have good convergent validity for marijuana use with other 
measures, including collateral reports from siblings and parents and urine testing,44 and is a 
reliable method of quantifying alcohol and marijuana use in adolescents in primary care.45 
Because the frequency-of-use variables were highly skewed, a dichotomized use/no use variable 
was constructed in which any past-12-month use at the 12-month followup was the primary 
outcome. Rates of initiation and cessation in baseline nonusers and users, respectively, were also 
calculated. This study only analyzed marijuana use because of the low prevalence of use of all 
other drugs (≤2%). Analyses were stratified by country because the two cohorts had different 
demographic characteristics. The asynchronous design was this study’s major threat to validity, 
as it precluded allocation concealment and blinding of assessors. There was also fairly high 
attrition among participants in the United States, with 72.4 percent of adolescents providing 12-
month data (compared with a 90.4% response rate in the Czech Republic). The validity of the 
results were strengthened, however, by the relatively large sample sizes (United States: n=2,106; 
Czech Republic: n=589) and statistical methods, including controlling for demographics, 
peer/family substance use, visit/provider characteristics, and the multisite sampling design in 
logistic regression models with generalized estimating equations.  
 
A very small fair-quality RCT conducted by Rhee and colleagues published in 2008 and based in 
the United States specifically recruited adolescents and young adults ages 14 to 20 years with a 
current diagnosis of asthma (n=41).39 This study targeted adolescents with asthma based on data 
showing that they have higher rates of current smoking and marijuana and inhalant use than 
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 adolescents without asthma—all behaviors which put them at high risk of asthma-related 
morbidity and mortality. Baseline risk of illicit drug use, alcohol use, and smoking are presented 
in Table 5 and Table 6. Use of illicit drugs and alcohol appeared to be generally low in 
participants; however, they were smoking, on average, 6.5 cigarettes per day for the past 30 days. 
Participants were recruited from rural outpatient clinics and one high school. While the 
intervention’s setting was not reported, we assume it took place in a research center/clinic. The 
intervention was based on a computer-assisted decisionmaking program that included a brief, 10-
minute counseling session conducted by a researcher (a family nurse practitioner) who educated 
participants about the harmful effects of tobacco, alcohol, and drug use in the context of asthma. 
The interventionist was able to tailor counseling to the participants’ prescribed asthma 
medications. Additionally, each participant completed two 1-hour computer-based (CD-ROM) 
educational modules. Module 1 was an interactive decisionmaking module that depicted 17 
different decisional situations, including smoking, alcohol, and “street” drug use. Module 2 was 
a noninteractive risk behavior module including information about smoking and alcohol only. 
Intervention boosters consisting of repeating the decisionmaking CD-ROM module and a 
workbook and a new interactive CD-ROM on substance use decisions were mailed at 2 and 4 
months, respectively. Participants in the control group were given a sham CD-ROM program 
(“featuring study skills”) that ran for a comparable duration as the intervention modules. 
Intervention fidelity and participant adherence were also not reported. The Periodic Assessment 
of Drug Use was administered at baseline and 2-, 4-, and 6-month followup to assess the 
frequency and amount of smoking, alcohol, and illicit drug use.46 Illicit drug use risk was 
constructed by combining the average frequencies of seven types of illicit drugs during the past 
year, including marijuana; lysergic acid diethylamide (LSD) or other hallucinogens; 
cocaine/crack; glue or inhalants; tranquilizers; “uppers,” such as speed; or “downers,” such as 
sedatives or sleeping pills.47 The validity, reliability, and responsiveness to change of this 
surveillance instrument are unknown.48 After 6 months of followup, 85.4 percent of the sample 
was retained. In terms of risk-of-bias, it was unclear if allocation to condition was concealed or if 
outcome assessors were blinded, although several participants completed followup measures 
online.  
 
The third fair-quality study, conducted by Walton and colleagues and published in 2013, 
evaluated the effectiveness of two different brief interventions designed to reduce marijuana use 
and its consequences in adolescents ages 12 to 18 years.42 All patients visiting one of seven 
Federally Qualified Community Health Clinics were screened for marijuana use (n=1,146) and 
subsequently randomly assigned to one of the intervention arms or control if they reported any 
past-year marijuana use (n=328). Both intervention arms implemented a brief intervention: one 
was therapist-led (n=118) and the other was computer-based (n=100). The interventions 
incorporated motivational interviewing and included tailored, parallel content. The therapist-led 
intervention was facilitated by a research therapist trained in motivational interviewing. The 
computer-based intervention was a stand-alone interactive program that participants completed 
on a computer tablet at the clinic. Control group participants (n=110) received a brochure 
containing information on the harms of marijuana use and resources about substance abuse 
treatment and other leisure activities. Both interventions took approximately 35 to 40 minutes to 
administer (therapist-led: mean, 41 minutes; computer-based: mean, 34 minutes).49 About two 
thirds of the sample was female, more than 60 percent was African American, and the average 
age was 16 years. At baseline, 100 percent reported past-year marijuana use (required to be 
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 eligible). More than 90 percent reported having experienced some negative consequence related 
to their marijuana use and 21 percent reported driving while under the influence of marijuana in 
the past 3 months. Twenty percent of participants reported other drug use besides marijuana and 
about half reported alcohol use in the past 3 months. Past-3-month frequency of marijuana and 
other drug use (i.e., inhalants, cocaine, heroin, other hallucinogens, and the nonmedical use of 
painkillers/opioids, stimulants, and sedatives) was measured using items adapted from the Add 
Health survey.50 Response choices were on a 7-point scale and ranged from 0 = never to 6 = 
every day or almost every day (see Table 5 for a full description of the scale). In addition, more 
than 80 percent of the sample provided a urine drug screen at each time point to determine 
concordance with the marijuana use self-report measures. Concordance was generally high at 
baseline (100%), 3 months (96.1%), 6 months (96.8%), and 12 months (98.5%). Given the low 
rates of discordance and fairly equal distribution of discordance across groups, reported 
outcomes were based on self-report. Marijuana-related consequences in the past 3 months 
included 28 items that addressed issues such as interpersonal consequences (e.g., “got in a fight”) 
and symptoms of a substance use disorder (e.g., “kept smoking when you promised yourself not 
to”). The scale was based on the Rutgers Alcohol Problem index (23 items, 5-point scale) and 
Severity of Dependence Scale (5 items, 4-point scale), with a range from 0 to 107. A single item 
on a 5-point scale assessed the frequency of driving under the influence of marijuana in the past 
3 months. This study had minimal threats to internal validity; the one concern was somewhat 
high attrition. At 12 months, 84 percent of the sample provided followup data, with 88, 77, and 
86 percent retention in the therapist-led, computer-based, and control groups, respectively.  
 
Computer-Based Interventions 
 
We included three RCTs that evaluated the effectiveness of the same computer-based prevention 
program for reducing substance use in adolescent girls, reported in four publications.36,37,40,41 The 
same group of authors conducted all three studies (Tables 3 and 4). The primary differences 
between the studies were the sample characteristics.  
 
All three studies implemented the same computer-based (i.e., Internet or CD-ROM) intervention 
designed for mother–daughter dyads. The intervention was based on family interaction theory 
and intervention objectives for the mothers were to improve communication with their daughters, 
monitor their daughters’ behaviors and activities, build their daughters’ self-image and self-
esteem, establish rules and consequences for substance use, and create family rituals. For the 
daughters, the program focused on building skills for managing stress, conflict, and mood; 
refusing peer pressure; and improving body esteem and self-efficacy. Mother–daughter dyads 
were asked to work together to complete nine 45-minute (once per week over 9 weeks) 
interactive sessions in their homes. Participants could not advance to the next program session 
unless the mother and daughter each answered questions correctly during the prior session. 
Additionally, only the dyads that had completed all nine program sessions could complete 
followup measures. Thus, the proportion of dyads that provided followup data reflects 
participants who had high compliance with the intervention. Two of the studies also included 
one36,37 or two41 45-minute annual booster sessions that were assumed to also be computer-based 
and similar in content, although this was not reported. Control group participants received no 
intervention.  
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 The samples within each study varied in size and demographic factors. The smaller 2009 “pilot” 
study conducted by Schinke et al,40 for example, randomized 591 pairs of adolescent girls ages 
11 to 13 years and their mothers from three northeastern U.S. states. These pairs were recruited 
through advertisements posted in local newspapers, online, in subway trains and buses, and 
broadcast on the radio. Nearly three quarters of the girls were of nonwhite race (48.9% African 
American and 24.7% Latina). The larger (n=916) 2009 study by the same authors also included 
pairs of adolescent girls ages 11 to 13 years and their mothers recruited similarly from the same 
three U.S. states.41 Similarly, just over three quarters of the girls were of nonwhite race (40.6% 
African American, 23.1% Latina, 10.8% Asian, and 1.7% other). These two studies utilized two 
distinct samples within the same time frame.51 In comparison, the study lead by Fang et al 
exclusively recruited and randomized 108 Asian American girls ages 11 to 14 years and their 
mothers within 19 U.S. states.36,37 Approximately one fifth of the girls and over half of the 
mothers were born outside of the United States.  
 
All three studies used the American Drug and Alcohol Survey self-report instrument to measure 
girls’ substance use at baseline and followup (Tables 5 and 6).52 This instrument has been 
shown to have an internal consistency of 0.72 to 0.94,41, 40 although no data on its validity or 
sensitivity to change has been published. All measures were administered online. In terms of 
substance use, all three studies measured the number of “use occasions” in the past 30 days in 
which girls had used marijuana, prescription drugs for nonmedical purposes, alcohol, and 
cigarettes. One study also reported past-30-day use occasions of inhalants.41 A use occasion 
score of 1.0 indicates a single use occasion of the respective substance in the past 30 days. At 
baseline, the number of use occasions for all substances was less than 1, indicating very low use, 
except for one study41 that reported 1.16 mean use occasions of alcohol and 1.03 mean use 
occasions of cigarettes at baseline (Table 6). These studies did not report the prevalence of use 
in participants. 
 
Two of the studies were rated good quality36,41 and the other was rated fair quality.40 While all 
three studies had more than 90 percent sample retention at 6 to 12 months, the one study rated as 
fair had more than 15 percentage points differential attrition between groups (i.e., retention in the 
intervention group at 12 months was 81.3%, whereas it was 96.5% in the control group).40 Two 
studies reported statistically significant differences in demographic characteristics or substance 
use behaviors between the groups at baseline, but both controlled for these differences in the 
analysis.  
 
Summary of Results 
 
Four of six trials reported some type of health outcome and findings were modest, mixed, or 
otherwise limited. One fair-quality, primary care–based study found no effects of either a 
therapist-led or computer-based brief intervention on self-reported marijuana-related 
consequences or driving under the influence of marijuana compared with the control group at 6 
or 12 months. Each of the three trials of the computer-based intervention reported depression 
outcomes, and only one found greater improvement in the intervention group compared with the 
control group at 6 months only. All six trials reported some type of substance use outcome. Four 
of the five studies reporting marijuana use found statistically significant differences in favor of 
the intervention group compared with the control group. The three computer-based trials also 
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 reported differences in nonmedical prescription drug use occasions. Individual studies reported 
additional substance use outcomes with mixed results. No studies reported on harms of the 
interventions.  
 
Detailed Results  
 
Morbidity, Mortality, and Other Health, Social, and Legal Outcomes (KQ 1) 
 
One primary care–based study42 and all three computer-based studies36,37,40,41 reported health 
outcomes from behavioral interventions to decrease substance use. In the primary care–based 
study by Walton and colleagues, the number of marijuana-related consequences significantly 
decreased in participants receiving the computer-based intervention at 3 and 6 months, while 
participants in the therapist-led group showed statistically significant decreases at 6 and 12 
months; there were no significant decreases seen in the control group.42 No statistically 
significant group-by-time interactions were seen at 6 or 12 months for either the computer-based 
or therapist-led groups compared with the control group (Table 7).  
 
All three computer-based studies compared differences in levels of depressed mood between the 
intervention and control groups at baseline and followup (Table 8).36,37,40,41 In one study, the 
intervention group reported less depressed mood than the control group at 6 months (p=0.045). 
This finding, however, did not hold true over 2 years.36,37 The other two studies did not find 
statistically significant differences between groups. No studies reported other health, social, or 
legal outcomes that might relate to drug use in children and adolescents, such as drug-related 
injuries or accidents, other risky behaviors (e.g., unprotected sex), educational attainment, or 
impaired driving.  
 
Behavioral Outcomes (KQ 2) 
 
Table 5 presents the results of each study according to the specific drug use outcome. The 
specific outcome measure varied across the studies. Four of the six studies found statistically 
significant differences in marijuana use at 12 to 24 months favoring the intervention group over 
the control group.36-38,40,41 In the cohort of U.S. adolescents in the study conducted by Harris and 
colleagues, there were lower rates of any marijuana use and marijuana initiation in intervention 
participants compared with control participants and higher rates of cessation at 12 months. These 
differences, however, were not statistically significant (Table 5). In contrast, in the Czech 
Republic cohort, 17.0 percent of participants in the intervention group reported past-12-month 
use of marijuana compared with 28.7 percent of control participants (risk ratio [RR], 0.47 [95% 
confidence interval [CI], 0.32 to 0.71]; p<0.05) at 12 months, after adjusting for multisite 
sampling; baseline past-12-month use; age; sex; parent education level; type of health care visit; 
perceived parent, sibling, and peer substance use; provider sex; and connectedness to provider.38 
Similarly, statistically significantly fewer adolescents in the intervention group reported 
initiating marijuana use during the past 12 months compared with those in the control group who 
initiated marijuana use (9.7% vs. 20.5%; RR, 0.47 [95% CI, 0.29 to 0.76]; p<0.05). Likewise, 
more participants in the intervention group reported quitting marijuana use (39.5% vs. 19.4% in 
the intervention vs. control groups, respectively; RR, 2.53 [95% CI, 1.06 to 6.05]; p<0.05). The 
study by Rhee did not find that the intervention had a statistically significant effect on the mean 
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 illicit drug use risk score in adolescents with asthma at 6 months.39 In the Walton study, all three 
conditions showed significant decreases in the frequency of marijuana use over time; however, 
group-by-time interactions were not significant for marijuana use frequency for either the 
therapist-led or computer-based interventions. Regarding the frequency of other drug use, there 
was a significant effect of the computer-based intervention at 6 months, but not 12 months; there 
was no effect of the therapist-led intervention on other drug use at any time point.42  
 
All three computer-based studies found statistically significant group-by-time effects in favor of 
the intervention in the number of marijuana use occasions in the past 30 days. As shown in 
Table 5, while marijuana use tended to increase in both the intervention and control groups over 
time, there was a statistically significant time-by-condition effect at 1240 and 24 months.37,41 Use 
occasions remained generally low for marijuana and inhalant use (i.e., <1.0 occasion per month) 
in both groups; however, instances of prescription drug use for nonmedical purposes increased at 
12 months (1.6 use occasions) and 24 months (3.6 use occasions) in the control group in the 
study of Asian American girls.36,37  
 
The three computer-based studies all reported statistically significant changes from baseline to 1- 
and 2-year followups favoring the intervention group over the control group in reduced 
nonmedical use of prescription drugs.37,40,41 Use occasions of prescription drugs were generally 
higher than marijuana for all three samples, although use was still generally low (range, 0.09 to 
0.64 at baseline across groups). In all three studies, use occasions of prescription drugs decreased 
in the intervention group over time, whereas use increased in the control group. One of the 
studies41 also found that the intervention group reported fewer occasions of inhalant use than the 
control group (p<0.024).  
 
Results related to alcohol use were generally consistent with the marijuana use outcomes (Table 
6). All three computer-based studies found that girls receiving the intervention reported 
significantly fewer instances of using alcohol compared with girls in the control group.37,40,41 The 
study conducted by Harris and colleagues reported statistically significantly less alcohol use and 
initiation in adolescents in the intervention group compared with the control group in the U.S. 
cohort, and no significant differences among the adolescents in the Czech Republic. 
Interestingly, rates of any alcohol use in the Czech Republic were more than double the rates in 
the United States (59.6% vs. 28.5%).38 The recent study by Walton and colleagues42 found no 
effect of either intervention on past-3-month alcohol use frequency at any time point, and the 
study by Rhee also found no group differences for alcohol use outcomes after the intervention.39 
None of the four studies that reported cigarette use found a statically significant positive effect of 
the intervention.  
 
Subgroup Differences (KQs 1a, 2a) 
 
No data were found to explore whether some subpopulations benefited more from drug use 
interventions than others. Three of the four studies that found positive effects for marijuana use 
only included younger girls (ages 11 to 14 years); one of these studies only included Asian 
American girls and the other two included racially diverse samples. None of the studies explored 
the effects of the intervention based on the participants’ ages, risk level, or types or frequencies 
of substances used.  
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 Elements of Efficacious Interventions (KQs 1b, 2b) 
 
We qualitatively examined a number of specific intervention characteristics (e.g., computer-
assisted interventions, hours of contact, role of primary care provider, individual targeted) and 
study design issues (e.g., measurement of drug use) to see if they were associated with effect 
size. All four studies that found positive effects for marijuana use included a computer-based 
intervention component; three of the four studies tested the same nine-session computer-based 
program that was completed by mother–daughter dyads. The other study utilized a computer-
based screening and educational module followed by brief provider advice during one primary 
care visit. Given the small number and heterogeneity of included interventions, however, we do 
not believe there is a clear pattern that explains why some trials had beneficial effects and others 
did not.  
 
Screening Criteria (KQs 1c, 2c) 
 
Only one study screened participants for their history of drug use prior to enrolling them in the 
study. In this study, only adolescents who reported any past-year marijuana use were included. 
Adolescents who reported never using marijuana were enrolled in a prevention study. The three 
computer-based studies relied on volunteer samples recruited from the community and set no 
criteria for current or past drug use for eligibility to enroll in the trial.  
 
Key Question 3. What Are the Adverse Events of Primary 
Care–Relevant Behavioral Counseling Drug Use 
Interventions? 
 
We identified no studies that reported adverse events related to interventions to reduce illicit 
drug use or nonmedical use of prescription drugs in children and adolescents. 
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 Chapter 4. Discussion 
 
Summary of Evidence 
 
We conducted this systematic review to assist the USPSTF in updating its 2008 recommendation 
on screening and interventions for drug misuse in children and adolescents. Our review included 
six primary care–relevant studies examining the benefits of interventions designed to reduce 
substance use, including the use of illicit drugs or the nonmedical use of prescriptions drugs in 
children and adolescents who are not seeking or identified as needing treatment. While three of 
these studies were conducted in or recruited directly from primary care, they varied in the 
populations they included. One study was conducted in primary care pediatric patients in the 
United States and Czech Republic, one study was conducted in adolescents with a diagnosis of 
asthma, and one study was conducted in adolescents recruited from primary care who reported 
past-year marijuana use. The three remaining studies were all performed by the same set of 
authors and tested the same computer-based intervention in mother–daughter pairs recruited 
through newspaper and other media advertisements. Only one of the studies focused on 
marijuana use specifically. The remaining studies targeted substance use more broadly—
focusing on reducing alcohol, drug, and, in some cases, tobacco use. The six included studies 
were generally of fair methodological quality, with various threats to internal validity.  
 
Table 9 presents an overall summary of the evidence. The included studies presented minimal 
evaluation of health, social, and legal outcomes. One study found no differences in the frequency 
of marijuana use–related consequences or driving while under the influence of marijuana; none 
of the computer-based studies found less depressed mood in the intervention group compared 
with the control group at 12 or 24 months. None of the other studies reported on other health, 
social, or legal outcomes, such as drug-related injuries or accidents, other risky behaviors, or 
educational attainment. It is not surprising that these studies omitted these outcomes, given that 
the interventions focused on samples of children and adolescents who reported low levels of drug 
use in general. Such problems might be more prevalent in a population of adolescents with more 
problematic use, including drug abuse or dependence.  
 
Four of the five studies that measured marijuana use before and after the intervention found 
greater benefit in the intervention group than the control group. The three computer-based 
studies reported marijuana outcomes as drug “use occasions” during the past 30 days, an 
uncommon summary measure that is difficult to interpret clinically. At 12 months, the range of 
use occasions was 0 to 0.10 in the intervention groups and 0.11 to 0.20 in the control groups, 
where a score of 1.0 indicates a single use occasion during the past 30 days. These three studies 
also found that use occasions of prescription drugs decreased in the intervention group over time, 
whereas use increased in the control group. One of the studies also found favorable outcomes in 
occasions of inhalant use. None of the studies reported adverse events related to the intervention.  
 
Screening for Drug Misuse 
 
Only two of the included studies employed a screening tool to determine whether or not 
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 adolescents were at risk of substance misuse and were candidates for the intervention.38,42 In the 
Walton study, adolescents were only eligible for the intervention if they reported using marijuana 
at all in the past year based on one screening question. In another study,38 the intervention began 
with participants completing a computer-based self-administered screening questionnaire that 
asked about lifetime and past-12-month substance use followed by the CRAFFT screening 
instrument. If youth reported no previous substance use, they were directed to the question about 
riding in a car with someone under the influence. The CRAFFT results were used as the basis for 
the individually-tailored brief advice from the provider. 
 
The CRAFFT instrument was developed specifically for adolescents.43 The content and structure 
are provided in Figure 2. It is a six-item screening instrument that covers alcohol and other 
substance misuse. It is currently recommended for use by the American Academy of Pediatrics 
to screen for misuse of alcohol and other drugs.23,53 It is a brief screen, taking only 1 to 2 minutes 
to administer, and can be administered as an interview, self-report, or computerized (the latter 
two methods being preferred by adolescents).54 Each “yes” response in Part B scores 1 point. A 
total score of 2 or higher is considered a positive screen, indicating the need for further 
assessment. The higher the CRAFFT score, the higher the probability of a diagnosis of substance 
abuse or dependence.43,55  
 
A systematic review of the psychometric properties of the CRAFFT instrument conducted by 
Dhalla et al presents a comprehensive summary of its validity and reliability in adolescents and 
young adults.56 Across the 12 studies included in this review, CRAFFT was found to be 
applicable to the range of alcohol and other drug misuse problems in adolescence, from 
emerging problem use to abuse and dependence. The optimal cutoffs ranged from 1 or greater or 
4 or greater, depending on the patient population and setting. Sensitivities ranged from 0.61 to 
1.00 and specificities from 0.33 (in sexually transmitted disease clinic patients) to 0.97. Criterion 
measures varied and included clinical and structured interviews. Internal consistency and test-
retest reliability were also examined. In adolescent primary care patients, the intraclass 
correlation coefficient for the lifetime and past-year CRAFFT total score was 0.93 and 0.91, 
respectively, at 1 week, indicating high test-retest reliability. The past-year CRAFFT score in 
particular had high test-retest reliability regardless of age or sex, and is the version recommended 
for screening.45 
 
Besides the CRAFFT screening tool, very few screening instruments that include questions on 
drug use have been developed and tested specifically in children and adolescents. Most screening 
instruments include questions about alcohol and/or tobacco use in addition to drug use (also 
known as “conjoint” screens) or are modifications of validated alcohol screening instruments. 
The CRAFFT items were developed from the longer Problem-Oriented Screening Test for 
Teenagers (139 items, self-administered),57 the Drug and Alcohol Problem Quickscreen (30 
items, self-administered),58 and the Relax, Alone, Friends, Family, Trouble (RAFFT) 
questionnaire (five items, not validated in adolescent populations).59 The Simple Screening 
Instrument for Alcohol and Other Drug Abuse has also shown good internal consistency and test-
retest reliability in adolescents receiving care at an adolescent/young adult medical practice.60 
The Alcohol and Drug Abuse Institute at the University of Washington houses a virtual, 
searchable database of substance use screening and assessment instruments that lists the details 
of over 900 instruments (available at http://lib.adai.uw.edu/instruments/). Additionally, there are 
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 a number of screening instruments available to identify substance misuse or a substance use 
disorder in adults that have been described elsewhere.2,61  
 
Limitations of the Review 
 
This review has a number of limitations, some of which are related to the body of evidence and 
some that are related to our approach. As was evident, we were able to include very few studies 
that were primary care–relevant and tested the effects of a behavioral intervention designed to 
reduce drug use in youth not meeting diagnostic criteria for drug abuse or dependence. The 
majority of the literature in this area was not relevant to our review, as it relates to the 
effectiveness or comparative effectiveness of drug abuse and dependence treatment in specialty 
outpatient settings, which is outside the primary care focus of this review. The majority of these 
adolescents were mandated to attend treatment by the criminal justice system or by their parents. 
An example of this type of study is the Cannabis Youth Treatment study, which found that 
motivational enhancement therapy plus cognitive behavioral therapy, adolescent community 
reinforcement approach, and multidimensional family therapy were all effective in increasing 
days of abstinence from marijuana and the percent of adolescents in recovery.62-64  
 
We found minimal evidence on reducing drug use in general U.S. primary care samples. One 
study specifically enrolled adolescents with asthma and three studies included only girls. Only 
two studies included screening for drug use. There were no studies that specifically addressed 
youth who are misusing or identified as having harmful use that had not yet progressed to abuse 
or dependence (i.e., “at risk”). Therefore, the available evidence offers little direction for a 
provider seeking to treat a drug-using adolescent to prevent progression to a drug disorder. The 
included studies enrolled adolescents regardless of their current and past drug use, except for one 
study that only enrolled adolescents who reported past-year marijuana use. Given the low 
prevalence of drug use in the samples, one can presume that the majority of youth were not using 
drugs or had very low use, while a few individuals could be progressing toward more harmful 
use. Only one study appears to have tailored the intervention based on the adolescents’ reports of 
their past-12-month drug use and associated risks.38 Because we did not include studies of drug 
abusing or dependent adolescents, we did not examine the role that primary care–based 
interventions can play in helping to identify and refer these patients to specialty care. To our 
knowledge, there are no studies in youth that test the full SBIRT model for problematic drug 
use—that is, screening and brief intervention or treatment with or without referral. There are a 
number of trials underway for adults that address components of the SBIRT model (such 
as http://clinicaltrials.gov/ct2/show/NCT00876941?term=saitz&rank=1). 
 
The scope of this report was limited to studies that were deemed to be relevant to primary care 
settings. As such, we only included studies that were linked to primary care or could be feasibly 
administered within primary care or the health care system. Other health care settings, schools, 
and juvenile and social system settings may also offer opportunities to provide behavioral 
interventions to reduce drug use in children and adolescents. While we would have included 
studies conducted in EDs, no studies that took place in an ED met all other eligibility criteria. 
One study in particular, conducted by Bernstein and colleagues,65 tested the effects of screening 
and brief intervention for youth and young adults ages 14 to 21 years presenting to the pediatric 
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 ED. All patients visiting the ED were invited to participate in the study and screened for early 
use of marijuana. Eligible participants were randomized to the control or intervention (n=210) 
group—a 20- to 30-minute structured conversation delivered by a peer educator in addition to 
written materials and booster telephone calls. At the 12-month followup, 45 percent of those in 
the intervention group reported being abstinent from marijuana use compared with 22 percent of 
the control group (odds ratio, 2.89 [95% CI, 1.22 to 6.84]; p=0.014). This study was not included 
in our evidence synthesis because the majority of patients were age 18 years and older and the 
study’s results were not stratified by age.  
 
We also excluded studies that did not include followup data at 6 months or longer given their 
limited generalizability on persistent behavioral or health effects. There were, however, a few 
relevant studies that reported outcomes at 3 months. For example, a study by D’Amico and 
colleagues66 evaluated the effect of a brief motivational interviewing intervention on alcohol and 
drug use for high-risk adolescents in a primary care clinic (85.7% Hispanic/Latino). At the 3-
month followup, adolescents in the intervention group reported statistically significantly less 
marijuana use than adolescents assigned to usual care. These preliminary results show promise; 
there is a need to replicate this study as part of a larger trial with longer-term outcomes.  
 
We excluded one study because it was rated as poor quality.67 In this study, pregnant adolescent 
girls were recruited from two regional health clinics in the United States (n=212) to participate in 
a self-administered series of eight print educational modules about prenatal health prior to each 
prenatal visit or a usual care control group. Within the eight modules, two appear to have focused 
on drug use during pregnancy. Following each module, the girls met with a trained health worker 
to discuss the educational module. Medical outcome data related to maternal mortality and 
morbidity and a number of birth outcomes (e.g., prematurity, birth defects, and birth weight) 
were compared among intervention and control groups at approximately 5 to 7 months 
postbaseline assessment. Rates of maternal anemia and sexually transmitted diseases were 
statistically significantly higher in the control group than in the intervention group. Given the 
large number of comparisons made (n=25), however, it is unclear whether these differences 
reflect random variability or reliable differences. Additionally, the biological plausibility of these 
outcomes is questionable given the low prevalence of drug use by the girls. It is unlikely that the 
differences seen in the rates of anemia and sexually transmitted disease are due solely to 
exposure to the intervention and subsequent substance use. Other confounding factors, such as 
the girls’ socioeconomic, nutrition, and relationship status, may have had an influence on these 
health outcomes. This study found no differences in the proportion of girls who used marijuana 
or cocaine in the past 5 months at approximately 5- to 7-months followup. There were a number 
of threats to internal validity with this study. First, participants were assigned to their given 
treatment group based on their county of residence; thus, allocation concealment was not 
possible. The length of followup was not explicitly stated and was assumed to vary across 
participants. The analysis appears to have been conducted in study completers only, and there 
was no attempt to impute missing data. Additionally, it was unclear if the analyses controlled for 
baseline differences. There were also several statistical comparisons made for maternal and birth 
outcomes, as well as behavioral outcomes, so it is not clear if the differences shown reflect 
random variability or reliable differences in the outcomes.  
 
Studies were generally not designed to assess the effects of the interventions on health, social, 
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 and legal outcomes and did not evaluate long-term effects. Instead, these studies primarily 
focused on behavioral outcomes. All of the studies relied on self-reported measures of substance 
use in which social desirability bias may be of concern. The available studies also used 
inconsistent measures of drug use, which makes direct comparisons across studies difficult. The 
three computer-based studies that all found significant effects relied on a self-reported measure 
of marijuana, prescription drug, and inhalant drug use occasions, which has limitations in its ease 
of recall by participants and limited clinical applicability. Additionally, there is a concern with 
this group of computer-based studies that involved the same group of investigators. While 
replication is an important component for validating and improving the accuracy and precision of 
effects, there is a concern that study replication among the same team of researchers may lead to 
spurious confirmation of effects due to group allegiance and other biases.68 There is a clear need 
to continue replication of this intervention among other teams of investigators and using more 
sensitive measures of drug use. 
 
The lack of research on behavioral interventions, with or without screening or referral, is likely 
heavily influenced by ethical and logistical issues related to including children as human 
subjects. Assent from the child and parental or legal guardian permission are required, which 
may influence recruitment.69 Youth may have little interest in participating in a research study if 
they perceive that their parents might learn about their substance use, regardless of any 
assurances of confidentiality by the research team.  
 
Applicability 
 
Although all six trials were conducted completely or partially in the United States, these trials 
only have limited applicability to child and adolescent patients typically seen in U.S. primary 
care. Only half of the trials included boys, and one of these was limited to children with asthma. 
The three trials conducted exclusively in girls had no connection to a health care system and 
involved broad-based recruitment primarily targeting mothers (e.g., through Craigslist and other 
media announcements). The mothers in these trials likely had higher levels of motivation to 
participate than may be typical in primary care settings.  
 
Although all of the included interventions are applicable to primary care, only half of the studies 
were tested in primary care. Only one trial involved a primary care physician in the 
intervention.38 In the others, a research-hired family nurse practitioner39 or trained research 
therapist42 provided the intervention, or it was solely computer-based.36,40,41 
 
Two trials in particular had good applicability to U.S. primary care.38,42 These two trials recruited 
participants from primary care, the interventions were conducted in primary care, and in one, the 
primary care provider delivered part of the intervention. While both trials addressed marijuana 
and alcohol use, neither of the interventions reduced marijuana use in participants in the United 
States (although one was effective in adolescents in the Czech Republic). 
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 Future Research Needs 
 
We have a number of suggestions for areas of future research based on this review. Since there 
were a small number of studies of good methodological quality that examined the effectiveness 
of primary care–relevant interventions, there is a substantial need to design and replicate 
promising interventions in well-controlled trials in larger, more representative samples of 
children and adolescents. This research would include involving more diverse samples of 
children and adolescents (e.g., boys and girls, with or without preexisting health conditions, of 
varying ages and socioeconomic status). Given the limited number of studies, we were not able 
to answer any of the subkey questions on the effectiveness of interventions on subgroups or the 
elements of efficacious interventions. Additionally, while we deemed the three computer-based 
studies to be feasible and applicable to primary care, research is needed to test this particular 
intervention and other computer-based interventions in primary care populations using outcomes 
with clear clinical meaning. If these interventions were offered on a Web-based platform, 
clinicians could conceivably refer their patients to the program and then use their face-to-face 
time to check in and reinforce important messages. As noted below, there appear to be a number 
of ongoing studies in the area that capitalize on this technology, including screening and 
administering brief interventions via electronic mediums. There is also a need for standardization 
of outcome measures and followup times to allow for more direct comparisons and quantitative 
synthesis.  
 
This body of evidence focused on relatively low-risk adolescents. There is a need for more 
research on screening and brief interventions in primary care for high-risk adolescents, including 
those with problematic use or abuse. Stand-alone motivational interventions delivered in primary 
care may have the potential to treat problematic use and also may help facilitate adolescents to 
accept referrals to additional treatment. In addition, to our knowledge, there has been no attempt 
to comprehensively review and synthesize the evidence on screening and interventions for all 
substances (i.e., drug, alcohol, and tobacco use). Given the similar risk factors, prevalence, and 
natural history of these respective substances, it is likely that interventions designed to prevent or 
reduce their use would employ similar strategies. Brief motivational interventions, such as 
motivational interviewing and interventions based on the 5 A’s (Ask, Advise, Assess, Assist, and 
Arrange), show promise for preventing and reducing alcohol and tobacco use in adolescents and 
are the mainstay of the SBIRT model for substance use in adults. Future research should focus 
on high-risk adolescents and motivational interventions that target and are tailored for all 
substances. Given the volatile nature of adolescents’ behavior and the biological, psychological, 
and social transformations that happen during this developmental phase, research evaluating 
regular screening and brief advice about all risky behaviors is warranted.  
 
The results of our review are consistent with those of a related systematic review recently 
published on the SBIRT model for adolescent drug and alcohol use.70 This review included 
RCTs examining one or more SBIRT components (e.g., screening, brief intervention [≤3 
sessions], or referral to treatment) in participants ages 12 to 22 years. Despite including a wider 
range of settings (i.e., primary care, EDs, schools, and other community settings), only 13 studies 
were included and the majority of studies addressed brief interventions for alcohol use in 
adolescents seeking care in EDs. No included studies reported on the referral to treatment 
process for those individuals identified as needing additional care and no studies addressed the 
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 full spectrum of SBIRT. This review found promising findings for brief interventions in primary 
care (based on one study not included in our review66) and universal screening within schools for 
substance use.  
 
The next update for this topic could have access to substantially more literature, particularly if 
combined with studies focused on alcohol and tobacco. We identified 20 ongoing trials with 
potential relevance to this review (Appendix C). Although four appear to be completed, with 
plans to publish results prior to this review search period, no related publications were identified 
upon manual searching. The remaining studies appear to be ending within the next few years 
(2014 to 2016) or are ongoing. Most of these studies target adolescents and/or young adults and 
include screening and brief intervention to decrease substance use. Several of these studies 
appear to include Web-based or electronic screening and focus on marijuana use specifically. 
One study in particular in the developmental phase being conducted by The Center for 
Adolescent Substance Abuse Research at Children’s Hospital of Boston has developed a 
computerized version of motivational enhancement therapy called “VYou.” It includes eight 
interactive exercises that encourage high-risk youth to consider how using substances affects 
their values and goals, the pros and cons of using, and negative consequences of use they have 
experienced, and guides them through the process of developing a plan to change their use 
(http://www.ceasar.org/isbirt/).71 Patients coming to a primary care office are screened and the 
provider asks those with substance use to complete the program in two separate sessions on a 
personal computer via connection to a secure Web site. When the patient completes a session, 
the provider gets a notice, goes into the site, reviews what the patient did, and sends them a 
secure e-mail giving feedback on their responses.72 The same group of investigators has another 
trial underway that also looks particularly relevant.73  
 
Five of the other ongoing studies include parent-focused interventions to strengthen parent-child 
communication, coping with parental stress, and parental monitoring of risky behaviors. Three 
studies target adolescents with chronic medical or mental health conditions. Considering all 
substances together appears to be a trend in much of the screening and in-process literature. 
 
Response to Public Comments 
 
A draft version of this evidence report was posted for public comment on the USPSTF Web site 
from October 1 to October 28, 2013. We received comments from three unique organizations. 
All comments were reviewed and considered. There were no new substantive issues brought up 
during the public comment period that were not previously raised and resolved. However, we 
clarified a few details on our methods. Several comments made by one organization referred to 
the need for more primary research on brief interventions for high-risk adolescents and 
interventions that take place in schools and colleges. The latter studies are considered outside of 
the USPSTF’s scope. Therefore, no additional studies were included and no comments on the 
need for this research were incorporated into the final report. 
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 Conclusion 
 
The evidence on the effectiveness of primary care behavioral interventions to reduce drug use in 
adolescents is limited in quantity, quality, and generalizability. Computer-based interventions 
that are self-administered in the home at convenient times and involve parents and adolescents 
show promise; however, youth who are actively using drugs or have problematic use were not 
well represented in the included trials and primary care–based interventions were generally not 
effective. Applicability to U.S. primary care settings is also limited. We found no evidence of the 
adverse events of these interventions.  
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Figure 1. Analytic Framework 
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Figure 2. CRAFFT Screening Interview 
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Table 1. Stages of Substance Use in Children and Adolescents 
Stage of use Description 
No use/abstinence The time before an individual has ever used drugs or alcohol (more than a few sips) 
Experimentation The first 1 to 2 times that a substance is used and the adolescent wants to know how 
intoxication from using a certain drug(s) feels (sometimes also refers to extremely 
infrequent or nonpersistent use) 
Limited use Use together with ≥1 friends in relatively low-risk situations and without related problems; 
typically, use occurs at predictable time, such as on weekends 
Problematic/harmful use Use in a high-risk situation, such as when driving or babysitting; use associated with a 
problem such as a fight, arrest, or school suspension; or use for emotional regulation, 
such as to relieve stress or depression 
Substance abuse Drug use associated with recurrent problems or that interferes with functioning, as defined 
in the DSM-IV-TR. A maladaptive pattern of substance use leading to clinically significant 
impairment or distress as manifested by one (or more) of the following, occurring within a 
12-month period:  
1. Recurrent substance use resulting in a failure to fulfill major role obligations at work, 
school, or home (such as repeated absences or poor work performance related to 
substance use; substance-related absences, suspensions, or expulsions from school; 
or neglect of children or household)  
2. Recurrent substance use in situations in which it is physically hazardous (such as 
driving an automobile or operating a machine when impaired by substance use)  
3. Recurrent substance-related legal problems (such as arrests for substance-related 
disorderly conduct)  
4. Continued substance use despite having persistent or recurrent social or 
interpersonal problems caused or exacerbated by the effects of the substance (for 
example, arguments with spouse about consequences of intoxication and physical 
fights)  
Substance addiction 
(dependence) 
Loss of control or compulsive drug use, as defined in the DSM-IV-TR as “dependence.” A 
maladaptive pattern of substance use leading to clinically significant impairment or 
distress, as manifested by three (or more) of the following, occurring any time in the same 
12-month period:  
1. Tolerance, as defined by either of the following: a) A need for markedly increased 
amounts of the substance to achieve intoxication or the desired effect or b) Markedly 
diminished effect with continued use of the same amount of the substance  
2. Withdrawal, as manifested by either of the following: a) The characteristic withdrawal 
syndrome for the substance or b) The same (or closely related) substance is taken to 
relieve or avoid withdrawal symptoms  
3. The substance is often taken in larger amounts or over a longer period than intended  
4. There is a persistent desire or unsuccessful efforts to cut down or control substance 
use  
5. A great deal of time is spent in activities necessary to obtain the substance, use the 
substance, or recover from its effects  
6. Important social, occupational, or recreational activities are given up or reduced 
because of substance use  
7. The substance use is continued despite knowledge of having a persistent physical or 
psychological problem that is likely to have been caused or exacerbated by the 
substance (for example, current cocaine use despite recognition of cocaine-induced 
depression or continued drinking despite recognition that an ulcer was made worse 
by alcohol consumption)  
Secondary abstinence Maintenance of abstinence or re-establishing abstinence after substance relapse  
Adapted from Levy SJ, Kokotailo PK. Substance use screening, brief intervention, and referral to treatment for 
pediatricians. Pediatrics. 2011;128(5):e1330-40.23 
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Table 2. Current (Past Month) Illicit Drug, Alcohol, and Cigarette Use, 2011 National Survey on 
Drug Use in Health  
Illicit drug 
All 
adolescents 
(12–17 years) 
Male 
adolescents 
(12–17 years) 
Female 
adolescents 
(12–17 years) 12–13 years 14–15 years 16–17 years 
Any illicit drug 10.1 10.8 9.3 3.3 9.2 17.2 
Marijuana 7.9 9.0 6.7 1.3 6.7 15.1 
Nonmedical use of 
any 
psychotherapeutic 
(pain relievers, 
specifically) 
2.8 (2.3) 2.4 (1.9) 3.2 (2.6) 1.3 (1.1) 2.6 (NR) 4.2 (NR) 
Cocaine 0.3 NR NR NR NR 0.5 
Hallucinogens 0.9 NR NR NR 0.8 1.6 
Inhalants 0.9 NR NR 1.0 0.9 0.7 
Alcohol 13.3 13.3 13.3 2.5 11.5 25.3 
Cigarettes 7.8 8.2 7.3 1.4 6.0 15.4 
Abbreviation: NR = not reported. 
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Table 3. Study Characteristics of Included Trials 
Author, Year 
Quality Rating 
Country, 
Intervention 
Setting 
Study 
Design 
IG N  
Enrolled/ 
Randomized 
CG N  
Enrolled/ 
Randomized 
F/U, 
m* 
% 
F/U Key Eligibility Criteria 
Age Range  
(mean), years 
%  
Female 
% 
Nonwhite 
Primary care–based 
Harris, 201238 
Fair 
U.S., primary 
care practices 
CCT  1,031 1,075 12 72.0 Patients ages 12–18 years 
arriving for routine primary 
care 
12–18 (15.8) 58.2 35.4 
Czech Republic, 
primary care 
practices 
CCT 292 297 12 90.0 13–17 (15.0) 47.2 0 
Rhee, 200839 
Fair 
U.S., research 
center  
RCT  20 21 6 85.4 Current diagnosis of 
asthma by health care 
provider 
14–20 (16.1) 68.3 31.7  
Walton, 201342 
Fair 
U.S., primary 
care clinics 
RCT TBI: 118 
CBI: 100 
 
110 12 83.8 Patients ages 12–18 years 
reporting past-year 
marijuana use 
12–18 (16.3) 66.5 60.7 
Computer-based 
Schinke, 
2009a40 
Fair 
U.S., computer-
based 
intervention at 
home 
RCT 252† 339† 12 90.0 Adolescent girls and their 
mothers who have private 
access to a personal 
computer 
11–13 (12.7) 100 73.6 
Schinke, 
2009b41 
Good 
U.S., computer-
based 
intervention at 
home 
RCT 458† 458† 12 94.3 Adolescent girls and their 
mothers who have private 
access to a personal 
computer 
11–13 (12.8) 100 76.8 
Fang, 201036,37 
Good 
U.S., computer-
based 
intervention at 
home 
RCT 56† 52† 12 96.3 Asian American adolescent 
girls and their mothers who 
have private access to a 
personal computer 
11–14 (13.1) 100 100 
*Longer followup times may be available; the common followup time in the included trials is reported. 
†Number of mother–daughter dyads. 
 
Abbreviations: CBI = computer-based brief intervention; CCT = clinical controlled trial; CG = control group; F/U = followup; IG = intervention group; N = sample 
size; NR = not reported; RCT = randomized, controlled trial; TBI = therapist-led brief intervention. 
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Table 4. Intervention Characteristics of Included Trials 
Author, 
Year 
Behavioral 
Targets 
Person 
Targeted Intervention Description Role of PC 
Mode of 
Intervention 
Duration of 
Intervention 
Estimated Time 
of Intervention 
Control Group 
Description 
Primary care–based 
Harris, 
201238 
Alcohol and 
drugs 
 
Child Self-administered computer-
facilitated screening asking about 
lifetime and past-12-month drug 
use followed by the CRAFFT 
questionnaire. Upon completion, 
the individual's CRAFFT score and 
risk level were displayed. 
Adolescents completed 
educational computer program 
containing information about drug 
use. The computer program was 
followed by brief provider advice 
informed by the adolescent’s 
screening results.  
Conducted in and 
recruited from PC, 
provider delivered 
part 
Face, 
computer 
1 visit  8 minutes (2–3 
minutes with 
interventionist) 
Usual care 
Rhee, 
200839 
Alcohol, 
tobacco, and 
illicit drugs 
 
Child Brief counseling by family nurse 
practitioner and CD-ROM 
programs. The CD-ROM contained 
a decisionmaking module on all 
substance use and provided 
information about smoking and 
alcohol use. Intervention booster 
CD-ROMs were mailed at 2- and  
4-month contacts. 
Recruited from PC, 
no provider role 
Face, 
computer 
1 visit + 2 
booster 
module 
mailings 
within 4 
months 
4.2 hours (10 
minutes with 
interventionist) 
Attention 
control 
Walton, 
201342 
Marijuana 
(primary), 
alcohol, other 
illicit and 
prescription 
drug use 
(secondary) 
Child Therapist-led brief intervention 
(TBI): motivational interviewing by 
trained research therapist 
Computer-based brief intervention 
(CBI): stand-alone interactive 
animated program 
Conducted in and 
recruited from PC 
Face (TBI), 
computer 
(CBI) 
1 visit 35–40 minutes 
(TBI: mean, 41 
minutes; CBI: 
mean, 34 
minutes) 
Enhanced 
usual care 
Computer-based 
Schinke, 
2009a40 
Alcohol, 
tobacco, 
marijuana, 
prescription 
drugs and 
OTC for 
nonmedical 
use 
Child 
and 
parent 
Mother–daughter dyads completed 
9 weekly 45-minute computer-
based sessions at home. Each 
session was delivered through 
voice-over narration, skills 
demonstration, and interactive 
activities for mothers and 
daughters to complete jointly. 
No PC or provider 
role 
Computer 9 weeks  6.8 hours No 
intervention 
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Table 4. Intervention Characteristics of Included Trials 
Author, 
Year 
Behavioral 
Targets 
Person 
Targeted Intervention Description Role of PC 
Mode of 
Intervention 
Duration of 
Intervention 
Estimated Time 
of Intervention 
Control Group 
Description 
Schinke, 
2009b41 
Alcohol, 
tobacco, 
marijuana, 
prescription 
drugs for 
nonmedical 
use, and 
inhalants 
Child 
and 
parent 
Mothers and daughters each had 
private sessions addressing 
specific material. Joint session 
material covered importance of 
interpersonal relationships; 
depression from stress, pressure  
to succeed or look a certain way; 
emotional closeness; sharing 
difficult feelings about each other 
and illustrating important ways to 
be supportive of each other.  
No PC or provider 
role 
Computer 9 weeks + 2 
booster 
sessions 
within 2 
years 
8.3 hours No 
intervention 
Fang, 
201036,37 
Alcohol, 
tobacco, 
marijuana, 
and 
prescription 
drugs for 
nonmedical 
use 
Child 
and 
parent 
No PC or provider 
role 
Computer 9 weeks + 1 
booster 
session 
within 12 
months 
7.5 hours No 
intervention 
Abbreviations: NR = not reported; OTC = over-the-counter; PC = primary care. 
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Table 5. Results of Interventions in Included Trials, Drug Use Behavioral Outcomes 
Author, Year 
Quality Rating 
Setting and 
population (age) Instrument 
Primary Outcome 
Measure 
F/U, 
m 
IG  
N 
IG 
Results 
CG  
N 
CG 
Results Effect Size 
Between-Group 
Difference, 
p-value 
Primary care–based 
Harris, 201238 
U.S. cohort 
Fair 
Primary care 
practices 
Adolescents (12–
18 years) 
12-month 
timeline 
followback 
interview  
Any past marijuana use BL 765 12.4% 758 13.3% 0.77 (0.56, 1.05)§ NSD 
12  765 15.6% 757 17.5% 0.85 (0.61, 1.19)§ NSD 
Marijuana initiation║ 12  670 7.8% 656 8.8% 0.81 (0.54, 1.21)§ NSD 
Marijuana cessation‡ 12  95 29.5% 101 26.7% 1.01 (0.57, 1.78)§ NSD 
Harris, 201238 
Czech Republic 
cohort 
Fair 
Primary care 
practices 
Adolescents (13–
17 years) 
12-month 
timeline 
followback 
interview  
Any past marijuana use BL 264 14.4% 266 13.6% 1.02 (0.63, 1.64)§ NSD 
12  264 17.0% 265 28.7% 0.47 (0.32, 0.71)§ <0.05 
Marijuana initiation║ 12  226 9.7% 229 20.5% 0.47 (0.29, 0.76)§ <0.05 
Marijuana cessation‡ 12  38 39.5% 36 19.4% 2.53 (1.06, 6.05)§ <0.05 
Rhee, 200839 
Fair 
Research center 
Adolescents with 
asthma (14–20 
years) 
Periodic 
Assessment of 
Drug Use 
Illicit drug use risk 
score*, mean (SD) 
BL 20 2.10 (9.16) 21 4.05 (10.63) NR NSD 
6  17¶ 0.63 (1.37) 18¶ 3.31 (9.4) NR NSD 
Walton, 201342 
(Therapist-led 
brief intervention) 
Fair 
Primary care 
clinics 
Adolescents (12–
18 years) 
Add Health Marijuana use 
frequency, past 3 
months, mean (SD)** 
BL 118 3.1 (1.9) 110 3.3 (1.9) NR NSD 
6 102 2.4 (2.1) 97 2.0 (2.1) 0.25 (0.14)†† NSD 
12 104 2.6 (2.2) 94 2.1 (2.2) 0.15 (0.14)†† NSD 
Other drug use 
frequency, past 3 
months, mean (SD)** 
BL 118 0.5 (1.3) 110 1.2 (2.7) NR NSD 
6 102 0.3 (0.9) 97 1.2 (4.6) -0.48 (0.42)†† NSD 
12 104 0.4 (1.7) 94 0.6 (2.1) 0.33 (0.51)†† NSD 
Walton, 201342 
(Computer-based 
brief intervention) 
Fair 
Primary care 
clinics 
Adolescents (12–
18 years) 
Add Health  Marijuana use 
frequency, past 3 
months, mean (SD)** 
BL 100 3.1 (1.9) 110 3.3 (1.9) NR NSD 
6 79 2.0 (2.1) 97 2.0 (2.1) 0.08 (0.16)†† NSD 
12 77 2.0 (2.2) 94 2.1 (2.2) -0.03 (0.16)†† NSD 
Other drug use 
frequency, past 3 
months, mean (SD)** 
BL 100 0.9 (3.0) 110 1.2 (2.7) NR NSD 
6 79 0.1 (0.5) 97 1.2 (4.6) -1.41 (0.52)†† <0.01† 
12 77 0.5 (2.1) 94 0.6 (2.1) 0.21 (0.48)†† NSD 
Computer-based 
Schinke, 2009a40 
 
Fair 
Home 
Adolescent girls 
(11–13 years) and 
their mothers  
American Drug 
and Alcohol 
Survey 
Marijuana, use 
occasions in the past 30 
days, mean (SD) 
BL 252 0.08 (0.01) 339 0.08 (0.02) NR NSD 
12  205 0.10 (0.13) 327 0.20 (0.65) NR <0.01† 
Prescription drugs (for 
nonmedical use), use 
occasions in the past 30 
days, mean (SD) 
BL 252 0.21 (0.96) 339 0.10 (0.47) NR NSD 
12  205 0.06 (0.46) 327 0.17 (1.58) NR <0.0001† 
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Table 5. Results of Interventions in Included Trials, Drug Use Behavioral Outcomes 
Author, Year 
Quality Rating 
Setting and 
population (age) Instrument 
Primary Outcome 
Measure 
F/U, 
m 
IG  
N 
IG 
Results 
CG  
N 
CG 
Results Effect Size 
Between-Group 
Difference, 
p-value 
Schinke, 2009b41 
Good 
Home 
Adolescent girls 
(11–13 years) and 
their mothers 
American Drug 
and Alcohol 
Survey 
Marijuana, use 
occasions in the past 30 
days, mean (SD) 
BL 458 0.08 (0) 458 0.09 (0) NR NSD 
12  434¶ 0.09 (0) 430¶ 0.11 (0.2) NR --- 
24  415¶ 0.10 (0.1) 413¶ 0.20 (0.7) NR <0.016† 
Prescription drugs, use 
occasions in the past 30 
days, mean (SD) 
BL 458 0.12 (0.2) 458 0.09 (0.1) NR NSD 
12  434¶ 0.09 (0) 430¶ 0.10 (0.1) NR --- 
24 415¶ 0.09 (0.1) 413¶ 0.11 (0.2) NR <0.03† 
Inhalants, use 
occasions in the past 30 
days, mean (SD) 
BL 458 0.04 (0.3) 458 0.01 (0.1) NR NSD 
12  434¶ 0.02 (0.2) 430¶ 0.04 (0.3) NR --- 
24 415¶ 0.02 (0.1) 413¶ 0.03 (0.2) NR <0.024† 
Fang, 201036,37 
Good 
Home 
Asian American 
girls (11–14 years) 
and their mothers  
American Drug 
and Alcohol 
Survey 
Marijuana, use 
occasions in the past 30 
days, mean (SD) 
BL 56 0.01 (0.12) 52 0.04 (0.19) NR NR 
12  54 0 (0) 50 0.12 (0.32) NR --- 
24 50 0 (0) 43 0.17 (0.38) NR 0.043† 
Prescription drugs, use 
occasions in the past 30 
days, mean (SD) 
BL 56 0.64 (2.98) 52 0.46 (1.64) NR NR 
12  54 0.07 (0.32) 50 1.6 (7.15) NR --- 
24 50 0 (0) 43 3.6 (12.99) NR 0.047† 
*Illicit drug use was constructed by combining the average frequencies of 7 types of illicit drugs in the past year, including marijuana; lysergic acid diethylamide 
(LSD) or other hallucinogens; cocaine/crack; glue or inhalants; tranquilizers; “uppers,” such as speed; or “downers,” such as sedatives or sleeping pills. 
†Time x intervention group interaction effects. 
‡Cessation analyzed only participants reporting any past-12-month use at baseline. 
§Adjusted relative risk ratio (95% confidence interval). In the U.S. cohort, adjusted by multisite sampling, baseline past-12-month substance use, age, sex, parent 
education level, type of visit, perceived parent, sibling and peer substance use, provider sex, and connectedness to provider. In the Czech Republic cohort, 
adjusted by multisite sampling, baseline past-12-month substance use, age, and sex. 
║Initiation analyzed only participants reporting no past-12-month use at baseline. 
¶N is assumed.  
**7-point scale: 0 = never; 1 = 1–2 days; 2 = once a month or less; 3 = 2–3 days per month; 4 = 1–2 days per week; 5 = 3–5 days per week; 6 = every day or 
almost every day. Other drugs included inhalants, cocaine, and sedatives. 
††Effect estimate (SE). 
 
Abbreviations: BL = baseline; CG = control group; F/U = followup; IG = intervention group; NR = not reported; NSD = no significant difference; SD = standard 
deviation; SE = standard error. 
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Table 6. Results of Interventions in Included Trials, Alcohol and Cigarette Behavioral Outcomes 
Author, Year 
Quality Rating 
Setting and 
population (age) Instrument 
Primary Outcome 
Measure 
F/U, 
m 
IG  
N 
IG  
Results 
CG  
N 
CG  
Results Effect Size 
Between-Group 
Difference,  
p-value 
Primary care–based 
Harris, 201238 
U.S. cohort 
Primary care 
practices 
Adolescents 
(12–18 years) 
 
12-month 
timeline 
followback 
interview 
(frequency of 
use) 
Any past alcohol use BL 765 25.4% 758 31.7% 0.82 (0.64, 1.06)§ NSD 
12  765 29.3% 758 37.5% 0.73 (0.57, 0.92)§ <0.05 
Alcohol initiation║ 12  571 11.9% 518 17.8% 0.66 (0.47, 0.93)§ <0.05 
Alcohol cessation‡ 12  194 19.6% 240 20.0% 1.50 (0.93, 2.42)§  NSD 
Harris, 201238 
Czech Republic 
cohort 
Primary care 
practices 
Adolescents 
(13–17 years) 
 
12-month 
timeline 
followback 
interview 
(frequency of 
use) 
Any past alcohol use BL 264 58.0% 266 61.3% 0.89 (0.76, 1.03)§ NSD 
12  264 70.1% 266 74.8% 0.96 (0.86, 1.04)§ NSD 
Alcohol initiation║ 12  111 33.3% 103 43.7% 0.76 (0.53, 1.08)§ NSD 
Alcohol cessation‡ 12  153 3.3% 163 5.5% 1.18 (0.37, 3.73)§ NSD 
Rhee, 200839 Research 
center 
Adolescents 
with asthma 
(14–20 years) 
Periodic 
Assessment 
of Drug Use 
Smoking risk score*, 
mean (SD) 
BL 20 1.05 (3.06) 21 1.26 (4.39) NR NR 
6  17¶ 1.28 (4.99) 18¶ 1.69 (3.82) NR NSD 
Alcohol risk score**, 
mean (SD) 
BL 20 8.40 (22.40) 21 41.52 (161.54) NR NR 
6 17¶ 18.38 (44.98) 18¶ 7.0 (21.01) NR NSD 
Walton, 201342 
(Therapist-led 
brief 
intervention) 
Fair 
Primary care 
clinics 
Adolescents 
(12–18 years) 
Alcohol Use 
Disorder Test 
Alcohol use frequency, 
past 3 months, mean 
(SD)†† 
BL 118 0.8 (0.9) 100 1.0 (1.1) NR NSD 
12 104 0.9 (1.0) 94 0.8 (1.0) 0.37 (0.19)‡‡ 0.05 
Walton, 201342 
(Computer-
based brief 
intervention) 
Fair 
Primary care 
clinics 
Adolescents 
(12–18 years) 
Alcohol Use 
Disorder Test 
Alcohol use frequency, 
past 3 months, mean 
(SD)†† 
BL 100 0.9 (1.1) 100 1.0 (1.1) NR NSD 
12 77 0.6 (0.8) 94 0.8 (1.0) -0.16 (0.20)‡‡ NSD 
Computer-based 
Schinke, 
2009a40 
Home 
Adolescent girls 
(11–13 years) 
and their 
mothers 
American 
Drug and 
Alcohol 
Survey 
Cigarettes, use 
occasions in the past 
30 days, mean (SD) 
BL 252 0.03 (0.24) 339 0.03 (0.27) NR NSD 
12  205 0.05 (0.50) 327 0.11 (0.08) NR NSD† 
Alcohol, use occasions 
in the past 30 days, 
mean (SD) 
BL 252 0.15 (0.17) 339 0.16 (0.31) NR NSD 
12  205 0.17 (0.32) 327 0.31 (0.61) NR <0.05† 
Schinke, 
2009b41 
Home 
Adolescent girls 
(11–13 years) 
and their 
mothers 
American 
Drug and 
Alcohol 
Survey 
Cigarettes, use 
occasions in the past 
30 days, mean (SD) 
BL 458 1.02 (0.2) 458 1.04 (0.3) NR NSD 
12  434¶ 1.02 (0.4) 430¶ 1.14 (1.2) NR --- 
24  415¶ 1.05 (0.5) 413¶ 1.39 (3.6) NR NSD† 
Alcohol, use occasions 
in the past 30 days, 
mean (SD) 
BL 458 0.14 (0.2) 458 0.18 (0.3) NR NSD 
12  434¶ 0.15 (0.2) 430¶ 0.25 (0.5) NR --- 
24 415¶ 0.17 (0.3) 413¶ 0.33 (0.7) NR <0.006† 
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Table 6. Results of Interventions in Included Trials, Alcohol and Cigarette Behavioral Outcomes 
Author, Year 
Quality Rating 
Setting and 
population (age) Instrument 
Primary Outcome 
Measure 
F/U, 
m 
IG  
N 
IG  
Results 
CG  
N 
CG  
Results Effect Size 
Between-Group 
Difference,  
p-value 
Fang, 201036,37 Home 
Asian American 
girls (11–14 
years) and their 
mothers  
American 
Drug and 
Alcohol 
Survey 
Cigarettes, use 
occasions in the past 
30 days, mean (SD) 
BL 56 0.07 (0.42) 52 0.17 (0.88) NR NR 
12  54 0.02 (0.13) 50 0.44 (1.58) NR --- 
24 50 0.02 (0.14) 43 1.95 (9.87) NR NSD† 
Alcohol, use occasions 
in the past 30 days, 
mean (SD) 
BL 56 0.04 (0.19) 52 0.29 (0.80) NR NR 
12  54 0.04 (0.18) 50 0.54 (1.51) NR --- 
24 50 0.05 (0.30) 43 0.10 (2.94) NR 0.038† 
*Smoking risk based on the number of cigarettes per day in the past 30 days. 
†Time x intervention group interaction effects. 
‡Cessation analyzed only participants reporting any past-12-month use at baseline. 
§Adjusted relative risk ratio (95% confidence interval). In the U.S. cohort, adjusted by multisite sampling, baseline past-12-month substance use, age, sex, parent 
education level, type of visit, perceived parent, sibling and peer substance use, provider sex, and connectedness to provider. In the Czech Republic cohort, 
adjusted by multisite sampling, baseline past-12-month substance use, age, and sex. 
║Initiation analyzed only participants reporting no past-12-month use at baseline. 
¶N is assumed.  
**Alcohol use risk computed by multiplying the combined frequency of all 3 types of alcohol (beer, wine, and liquor) by the average quantity of drink per occasion in 
the past year. 
††5-point scale: 0=never, 1=less than monthly, 2=monthly, 3=weekly, 4=daily. 
‡‡Generalized estimating equations analyses comparing intervention vs. control by time, estimate (SE). 
 
Abbreviations: BL = baseline; CG = control group; F/U = followup; IG = intervention group; NR = not reported; NSD = no significant difference; SD = standard 
deviation; SE = standard error. 
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Table 7. Results of Interventions of Included Studies, Marijuana-Related Consequences and Driving Under the Influence 
Author, Year 
Quality Rating 
Setting and 
population 
(age) Instrument 
Primary Outcome 
Measure 
F/U,  
m 
IG  
N 
IG  
Results 
CG  
N 
CG 
Results 
Effect 
Size (SE) 
Between-Group 
Difference,  
p-value 
Primary care–based 
Walton, 201342 
(Therapist-led 
brief 
intervention) 
 
Fair 
Primary care 
clinics 
 
Adolescents 
(12–18 
years) 
Modified Rutgers Alcohol 
Problems Index (23 items) 
and Severity of Dependence 
Scale (5 items) 
Number of marijuana-
related consequences, 
past 3 months, mean 
(SD)* 
BL 118 14.2 (15.3) 100 14.0 (15.0) NR NSD 
6 102 11.3 (12.9) 97 11.0 (13.6) -0.08 (0.15) NSD 
12 104 11.1 (13.0) 94 11.5 (14.4) -0.07 (0.15) NSD 
Single item Driving under the 
influence of marijuana 
frequency, past 3 
months, mean (SD)† 
BL 118 0.4 (0.9) 100 0.3 (0.7) NR NSD 
6 102 0.3 (0.8) 97 0.4 (0.9) -0.68 (0.41) NSD 
12 104 0.3 (0.9) 94 0.3 (0.9) -0.32 (0.41) NSD 
Walton, 201342 
(Computer-
based brief 
intervention) 
 
Fair 
Primary care 
clinics 
 
Adolescents 
(12–18 
years) 
Modified Rutgers Alcohol 
Problems Index (23 items) 
and Severity of Dependence 
Scale (5 items) 
Number of marijuana-
related consequences, 
past 3 months, mean 
(SD)* 
BL 100 14.3 (15.5) 100 14.0 (15.0) NR NSD 
6 79 10.5 (13.6) 97 11.0 (13.6) -0.15 (0.16) NSD 
12 77 12.7 (13.8) 94 11.5 (14.4) 0.08 (0.17) NSD 
Single item Driving under the 
influence of marijuana 
frequency, past 3 
months, mean (SD)† 
BL 100 0.5 (1.1) 100 0.3 (0.7) NR NSD 
6 79 0.5 (1.1) 97 0.4 (0.9) -0.34 (0.37) NSD 
12 77 0.5 (1.0) 94 0.3 (0.9) -0.17 (0.44) NSD 
*Rutgers Alcohol Problem index (23 items, 5-point scale) and Severity of Dependence Scale (5 items, 4-point scale), range: 0–107. 
†5-point scale: 0=never, 1=1–2 times, 2=3–5 times, 3=6–9 times, 4=10 or more times. 
 
Abbreviations: BL = baseline; CG = control group; F/U = followup; IG = intervention group; NR = not reported; NSD = no significant difference; SD = standard 
deviation; SE = standard error. 
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Table 8. Results of Interventions of Included Studies, Depressed Mood Outcomes 
Author, Year 
Quality Rating 
Setting and 
population (age) Instrument 
Primary Outcome 
Measure 
F/U, 
m 
IG  
N 
IG  
Results 
CG  
N 
CG  
Results 
Time x Intervention 
Group Effect, p-value 
Computer-based 
Schinke, 
2009a40 
Fair 
Home 
Adolescent girls  
(11–13 years) and 
their mothers 
Children’s 
Depression 
Inventory 
Depression, mean 
(SD)* 
BL 252 1.62 (0.77) 339 1.71 (0.79) NSD 
12  205 1.52 (0.84) 327 1.79 (0.80) NSD 
Schinke, 
2009b41 
Good 
Home 
Adolescent girls  
(11–13 years) and 
their mothers 
Children’s 
Depression 
Inventory 
Depression, mean 
(SD)* 
BL 458 3.42 (0.7) 458 3.28 (0.8) <0.05 
12  434† 3.45 (0.8) 430† 3.30 (0.8) --- 
24  415† 3.48 (0.8) 413† 3.23 (0.8) NSD 
Fang, 201036,37 
Good 
Home 
Asian American girls 
(11–14 years) and 
their mothers 
Children’s 
Depression 
Inventory  
Depression, mean 
(SD)* 
BL 56 1.36 (0.84) 52 1.66 (0.62) NR 
12  54 1.23 (0.71) 50 1.71 (0.75) --- 
24 50 1.23 (0.87) 43 1.67 (0.65) NSD 
*Scores are 5-item scales in which lower scores are better.  
†N is assumed.  
 
Abbreviations: BL = baseline; CG = control group; IG = intervention group; NR = not reported; NSD = no significant difference; SD = standard deviation. 
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Table 9. Summary of Evidence for Benefits and Harms of Drug Use Interventions 
Intervention 
Trials, k 
Observations, n Major limitations Consistency Applicability 
Quality 
ratings Summary of findings 
Key Question 1 (health, social, and legal outcomes) 
Primary care-
based 
k=1, n=328 Only 1 trial. NA Good. Primary care–
screened population in 
the U.S.  
1: Fair No differences in marijuana use–related 
consequences at 12 months in primary 
care adolescents.  
Computer-
based 
k=3, n=1,615 Only 1 intervention was 
evaluated (with replication 
across 3 studies). No trials 
included boys. 
Not 
consistent 
Fair. No links to 
primary care, 
volunteer samples, all 
conducted in U.S. 
2: Good 
1: Fair 
1 of 3 trials found that girls in the 
intervention group reported less 
depressed mood compared with girls in 
the control group after 6 months. 
Key Question 2 (behavioral outcomes) 
Primary care-
based 
k=3, n=3,064 Inconsistent outcome 
measurement.  
Not 
consistent 
Good. All studies in 
primary care, 1 study 
limited to asthma 
patients. 
3: Fair 1 of 3 trials found a statistically 
significant benefit of the intervention in 
adolescents in the Czech Republic (but 
not the U.S.) in terms of any marijuana 
use, marijuana initiation, and marijuana 
cessation.  
Computer-
based 
k=3, n=1,615 Only 1 intervention was 
evaluated (with replication 
across 3 studies). No trials 
included boys. Baseline and 
followup drug use measures 
were use occasions, which  
do not easily translate to 
clinical or public health 
benefit. 
Consistent  Fair. No links to 
primary care, 
volunteer samples, all 
conducted in U.S. 
2: Good 
1: Fair 
All trials found a statistically significant 
benefit of the intervention on marijuana 
use and nonmedical prescription drug 
use over 12 to 24 months. 1 trial also 
showed a significant effect for inhalant 
use. 
Key Question 3 (adverse effects) 
NA k=0 NA NA NA NA No studies assessed adverse effects 
of the intervention. 
Abbreviations: NA = not applicable. 
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Appendix A. Detailed Methods 
Systematic Review Search Strategies 
 
Database of Abstracts of Reviews of Effects (DARE) search strategy 
 
1 (addict* OR abuse* OR abusing OR misus* OR nonmedical OR "non medical"):ti,ab,kw IN 
DARE FROM 2007 TO 2012 
2 (drug OR drugs OR substance* OR opioid* OR opiate* OR prescription* OR 
psychotherapeutic*):ti,ab,kw IN DARE FROM 2007 TO 2012 
3 #1 AND #2 
4 (drug use* OR substance use* ):ti,ab,kw IN DARE FROM 2007 TO 2012 
5 #3 OR #4 
6 (child OR children OR teen OR teens OR teenage* OR adolescen* OR youth OR youths OR 
"young people"):ti,ab,kw IN DARE FROM 2007 TO 2012 
7 #5 AND #6 
 
MEDLINE (Ovid) search strategy   
Database(s): Ovid MEDLINE(R) without Revisions 1996 to November Week 3 2012, Ovid 
MEDLINE(R) Daily Update November 14, 2012, Ovid MEDLINE(R) In-Process & Other 
Non-Indexed Citations November 21, 2012 
 
# Searches 
1 substance-related disorders/ or amphetamine-related disorders/ or cocaine-related disorders/ 
or inhalant abuse/ or marijuana abuse/ or opioid-related disorders/ or heroin dependence/ or 
morphine dependence/ or phencyclidine abuse/ or substance abuse, intravenous/ 
2 Prescription Drug$.ti,ab,mh. 
3 ((drug or drugs or substance* or opioid* or opiate* or prescription* or psychotherapeutic*) 
adj3 (addict* or abuse* or abusing or misus* or nonmedical or non medical)).ti,ab. 
4 (drug use$ or substance use$).ti,ab. 
5 1 or 2 or 3 or 4 
6 Mass Screening/ 
7 screen$.ti,ab. 
8 6 or 7 
9 5 and 8 
10 substance abuse detection/ 
11 9 or 10 
12 adolescent/ or child/ 
13 (child$ or teen or teens or teenage$ or adolescen$ or youth or youths or young people).ti,ab. 
14 12 or 13 
15 11 and 14 
16 limit 15 to systematic reviews 
17 limit 16 to (english language and yr="2007 -Current") 
18 Behavior Therapy/ 
19 Cognitive Therapy/ 
20 Directive Counseling/ or Counseling/ 
21 Patient Education as Topic/ 
22 Risk Reduction Behavior/ 
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23 counsel$.ti,ab. 
24 advice.ti,ab. 
25 advise$.ti,ab. 
26 behavio?r$ chang$.ti,ab. 
27 behavio?r$ intervention$.ti,ab. 
28 behavio?r$ modification$.ti,ab. 
29 motivational interview$.ti,ab. 
30 substance-related disorders/dt, pc, rh, th or amphetamine-related disorders/dt, pc, rh, th or 
cocaine-related disorders/dt, pc, rh, th or inhalant abuse/dt, pc, rh, th or marijuana abuse/dt, pc, 
rh, th or opioid-related disorders/dt, pc, rh, th or heroin dependence/dt, pc, rh, th or morphine 
dependence/dt, pc, rh, th or phencyclidine abuse/dt, pc, rh, th or substance abuse, intravenous/dt, 
pc, rh, th 
31 (intervention$ or prevention or preventive or psychosocial).ti. 
32 or/18-31 
33 5 and 14 and 32 
34 limit 33 to systematic reviews 
35 limit 34 to (english language and yr="2007 -Current") 
36 17 or 35 
37 remove duplicates from 36 
   
PubMed search strategy (searched only for “publisher” unindexed references) 
 
#1 (drug[tiab] OR drugs[tiab] OR substance*[tiab] OR opioid*[tiab] OR opiate*[tiab] OR 
prescription*[tiab] OR psychotherapeutic*[tiab]) AND (ict*[tiab] OR abuse*[tiab] OR 
abusing[tiab] OR misus*[tiab] OR nonmedical[tiab] OR "non medical"[tiab]) 
#2 drug use*[tiab] OR substance use* [tiab] 
#3 #1 OR #2 
#4 screen* [tiab] 
#5 counsel*[tiab] 
#6 advice[tiab] 
#7 advise*[tiab] 
#8 behavi*[tiab] AND change*[tiab] 
#9 motivational*[tiab] AND interview*[tiab] 
#10 behavi*[tiab] AND intervention*[tiab] 
#11 behavi*[tiab] AND modification*[tiab] 
#12 #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 
#13 #3 AND #12 
#14 child[tiab] OR children[tiab] OR teen[tiab] OR teens[tiab] OR teenage* [tiab] OR 
adolescen* [tiab] OR youth[tiab] OR youths[tiab] OR "young people"[tiab] 
#15 #13 AND #14 
#16 #15 AND systematic[sb] 
#17 #16 AND publisher[sb] 
 
PsycINFO search strategy 
 
#1 Drug Abuse OR Drug Abuse Prevention OR Drug Addiction OR Drug Dependency OR Drug 
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Usage OR Intravenous Drug Usage OR Polydrug Abuse:Index Terms  
#2 (School Age (6-12 yrs) OR Adolescence (13-17 yrs)): Age Group 
#3 ( Systematic Review): Methodology 
#4 #1 AND #2 AND #3 AND [2007 TO 2012]:PublicationYear 
 
Key Question Search Strategies 
 
Ovid MEDLINE(R) without Revisions 1996 to January Week 1 2013, Ovid MEDLINE(R) 1988 
to 1995, Ovid MEDLINE(R) Daily Update January 15, 2013, Ovid MEDLINE(R) In-Process & 
Other Non-Indexed Citations January 15, 2013 
# Searches 
1 substance-related disorders/ 
2 amphetamine-related disorders/ 
3 cocaine-related disorders/ 
4 inhalant abuse/ 
5 marijuana abuse/ 
6 opioid-related disorders/ 
7 phencyclidine abuse/ 
8 substance abuse, intravenous/ 
9 ((drug or drugs or substance$ or opioid$ or opiate$ or prescription$ or psychotherapeutic$) 
adj3 (abuse$ or abusing or misus$ or nonmedical or non medical or extramedical or extra 
medical)).ti,ab. 
10 (drug use$ or substance use$).ti,ab. 
11 drug abstinence.ti,ab. 
12 street drugs/ 
13 hallucinogens/ 
14 marijuana.ti,ab. 
15 cocaine.ti,ab. 
16 methamphetamine.ti,ab. 
17 (mdma or ecstasy).ti,ab. 
18 lsd.ti,ab. 
19 ((ritalin or adderall or methylphenidate or oxycodone or hydrocodone or pain relief or pain 
reliever$ or pain medication$) adj3 (abuse$ or abusing or misus$ or nonmedical or non medical 
or extramedical or extra medical)).ti,ab. 
20 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 
19 
21 adolescent/ or child/ 
22 (child$ or teen or teens or teenage$ or adolescen$ or youth or youths or young people or 
pediatric$ or paediatric$).ti,ab. 
23 21 or 22 
24 Behavior Therapy/ 
25 Cognitive Therapy/ 
26 Counseling/ 
27 Directive Counseling/ 
28 Patient Education as Topic/ 
29 Risk Reduction Behavior/ 
Drug Misuse in Children and Adolescents 48  Kaiser Permanente Research Affiliates EPC 
Appendix A. Detailed Methods 
30 Feedback, psychological/ 
31 Health education/ 
32 Health promotion/ 
33 Motivation/ 
34 Internet/ 
35 Motivational interviewing/ 
36 Persuasive communication/ 
37 Preventive health services/ 
38 Self-help groups/ 
39 Text messaging/ 
40 Therapy, computer-assisted/ 
41 counsel$.ti,ab. 
42 advice.ti,ab. 
43 advise$.ti,ab. 
44 behavio?r$ chang$.ti,ab. 
45 behavio?r$ intervention$.ti,ab. 
46 behavio?r$ modification$.ti,ab. 
47 motivational interview$.ti,ab. 
48 (cognitive behavio$ or behavio$ therapy or cbt).ti,ab. 
49 brief intervention$.ti,ab. 
50 computer based.ti,ab. 
51 self help.ti,ab. 
52 email$.ti,ab. 
53 internet.ti,ab. 
54 text messag$.ti,ab. 
55 (web or website).ti,ab. 
56 (intervention$ or prevention or preventive or psychosocial).ti. 
57 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 
40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 
58 substance-related disorders/pc 
59 amphetamine-related disorders/pc 
60 cocaine-related disorders/pc 
61 inhalant abuse/pc 
62 marijuana abuse/pc 
63 opioid-related disorders/pc 
64 phencyclidine abuse/pc 
65 substance abuse, intravenous/pc 
66 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 
67 (clinical trial or controlled clinical trial or meta analysis or randomized controlled trial).pt. 
68 clinical trials as topic/ or controlled clinical trials as topic/ or randomized controlled trials as 
topic/ 
69 Meta-Analysis as Topic/ 
70 random$.ti,ab. 
71 clinical trial$.ti,ab. 
72 controlled trial$.ti,ab. 
73 67 or 68 or 69 or 70 or 71 or 72 
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74 20 and 23 and 57 and 73 
75 23 and 66 and 73 
76 74 or 75 
77 limit 76 to (english language and yr="1992 -Current") 
78 remove duplicates from 77 
 
PubMed (publisher subset only) 1/16/2013 
Search Query 
#26 Search #24 AND publisher[sb] Filters: Publication date from 1992/01/01 to 
2013/12/31; English Sort by: PublicationDate 
#25 Search #24 AND publisher[sb] 
#24 Search #22 AND #23 
#23 Search random*[tiab] OR clinical trial*[tiab] OR controlled trial*[tiab] 
#22 Search #10 AND #21 
#21 Search #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR 
#20 
#20 Search intervention*[ti] OR prevention[ti] OR preventive[ti] OR psychosocial[ti] 
#19 Search "patient education"[tiab] OR "health education"[tiab] OR "health 
promotion"[tiab] 
#18 Search email*[tiab] OR internet[tiab] OR text messag*[tiab] OR web[tiab] OR 
website[tiab] 
#17 Search cbt[tiab] OR brief intervention*[tiab] OR computer based[tiab] OR self 
help[tiab] 
#16 Search behavio*[tiab] AND therapy[tiab] 
#15 Search motivational interview*[tiab] OR cognitive behavio*[tiab] 
#14 Search behavio*[tiab] AND modification*[tiab] 
#13 Search behavio*[tiab] AND intervention*[tiab] 
#12 Search behavio*[tiab] AND chang*[tiab] 
#11 Search counsel*[tiab] OR advice[tiab] OR advise*[tiab] 
#10 Search #8 AND #9 
#9 Search child*[tiab] OR teen[tiab] OR teens[tiab] OR teenage*[tiab] OR 
adolescen*[tiab] OR youth[tiab] OR youths[tiab] OR "young people"[tiab] OR pediatric*[tiab] 
OR paediatric*[tiab] 
#8 Search #3 OR #4 OR #5 OR #7 
#7 Search #2 AND #6 
#6 Search ritalin[tiab] OR adderall[tiab] OR methylphenidate[tiab] OR 
oxycodone[tiab] OR hydrocodone[tiab] OR "pain relief"[tiab] OR pain reliever*[tiab] OR pain 
medication*[tiab] 
#5 Search marijuana[tiab] OR cocaine[tiab] OR methamphetamine[tiab] OR 
mdma[tiab] OR ecstasy[tiab] OR lsd[tiab] 
#4 Search drug use*[tiab] OR substance use*[tiab] 
#3 Search #1 AND #2 
#2 Search abuse*[tiab] OR abusing[tiab] OR misus*[tiab] OR nonmedical[tiab] OR 
"non medical"[tiab] OR extramedical[tiab] OR "extra medical"[tiab] 
#1 Search drug[tiab] OR drugs[tiab] OR substance*[tiab] OR opioid*[tiab] OR 
opiate*[tiab] OR prescription*[tiab] OR psychotherapeutic*[tiab] 
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Ovid PsycINFO 1987 to January Week 2 2013 
# Searches 
1 Drug Abuse/ 
2 Drug Usage/ 
3 Inhalant Abuse/ 
4 Glue Sniffing/ 
5 Polydrug Abuse/ 
6 Drug Abstinence/ 
7 Intravenous Drug Usage/ 
8 Marijuana Usage/ 
9 Cocaine/ 
10 Opiates/ 
11 Hallucinogenic Drugs/ 
12 Phencyclidine/ 
13 Methamphetamine/ 
14 Methylenedioxymethamphetamine/ 
15 Lysergic Acid Diethylamide/ 
16 ((drug or drugs or substance$ or opioid$ or opiate$ or prescription$ or psychotherapeutic$) 
adj3 (abuse$ or abusing or misus$ or nonmedical or non medical or extramedical or extra 
medical)).ti,ab. 
17 (drug use$ or substance use$).ti,ab. 
18 ((ritalin or adderall or methylphenidate or oxycodone or hydrocodone or pain relief or pain 
reliever$ or pain medication$) adj3 (abuse$ or abusing or misus$ or nonmedical or non medical 
or extramedical or extra medical)).ti,ab. 
19 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 
20 Health Promotion/ 
21 Motivation/ 
22 behavio?r$ chang$.ti,ab. 
23 behavio?r$ intervention$.ti,ab. 
24 behavio?r$ modification$.ti,ab. 
25 behavior therapy/ 
26 cognitive behavior therapy/ 
27 cognitive therapy/ 
28 Cognitive Techniques/ 
29 (cognitive behavio$ or behavio$ therapy or cbt).ti,ab. 
30 brief intervention$.ti,ab. 
31 Behavior Modification/ 
32 Behavior Change/ 
33 Persuasive Communication/ 
34 Motivational Interviewing/ 
35 motivational interview$.ti,ab. 
36 Health Knowledge/ 
37 Health Behavior/ 
38 Health Education/ 
39 Client Education/ 
40 Feedback/ 
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41 Online Therapy/ 
42 Computer Assisted Therapy/ 
43 Computer Mediated Communication/ 
44 Internet/ 
45 computer based.ti,ab. 
46 text messag$.ti,ab. 
47 email$.ti,ab. 
48 internet.ti,ab. 
49 (web or website).ti,ab. 
50 Self Help Techniques/ 
51 self help.ti,ab. 
52 counseling/ 
53 Group Counseling/ 
54 counseling.ti,ab. 
55 counselling.ti,ab. 
56 advice.ti,ab. 
57 advise$.ti,ab. 
58 (intervention$ or prevention or preventive or psychosocial).ti. 
59 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 
36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 
or 53 or 54 or 55 or 56 or 57 or 58 
60 19 and 59 
61 Drug Abuse Prevention/ 
62 60 or 61 
63 (adolescence 13 17 yrs or childhood birth 12 yrs).ag. 
64 (child$ or adolescen$ or teen$ or youth$ or young people or pediatric$ or paediatric$).ti,ab. 
65 63 or 64 
66 62 and 65 
67 treatment outcome clinical trial.md. 
68 Experiment Controls/ 
69 controlled trial$.ti,ab. 
70 clinical trial$.ti,ab. 
71 random$.ti,ab. 
72 meta analy$.ti,ab. 
73 metaanaly$.ti,ab. 
74 67 or 68 or 69 or 70 or 71 or 72 or 73 
75 66 and 74 
76 limit 75 to (english language and yr="1992 -Current") 
 
Cochrane Central Register of Controlled Trials, Issue 12 of 12, Dec. 2012  
#1 drug:ti,ab,kw or drugs:ti,ab,kw or substance*:ti,ab,kw or opioid*:ti,ab,kw or 
opiate*:ti,ab,kw or prescription*:ti,ab,kw or psychotherapeutic*:ti,ab,kw from 1992 to 2013, in 
Trials  
#2 abuse*:ti,ab,kw or abusing:ti,ab,kw or misus*:ti,ab,kw or nonmedical:ti,ab,kw or "non 
medical":ti,ab,kw or extramedical:ti,ab,kw or "extra medical":ti,ab,kw from 1992 to 2013, in 
Trials  
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#3 #1 and #2 from 1992 to 2013, in Trials  
#4 drug next use*:ti,ab,kw or substance next use*:ti,ab,kw from 1992 to 2013, in Trials  
#5 marijuana:ti,ab,kw or cocaine:ti,ab,kw or methamphetamine:ti,ab,kw or mdma:ti,ab,kw 
or ecstasy:ti,ab,kw or lsd:ti,ab,kw from 1992 to 2013, in Trials  
#6 ritalin:ti,ab,kw or adderall:ti,ab,kw or methylphenidate:ti,ab,kw or oxycodone:ti,ab,kw or 
hydrocodone:ti,ab,kw or "pain relief":ti,ab,kw or pain next reliever*:ti,ab,kw or pain next 
medication*:ti,ab,kw from 1992 to 2013, in Trials #7 #2 and #6 from 1992 to 2013, in 
Trials  
#8 #3 or #4 or #5 or #7 from 1992 to 2013, in Trials  
#9 child*:ti,ab,kw or teen:ti,ab,kw or teens:ti,ab,kw or teenage*:ti,ab,kw or 
adolescen*:ti,ab,kw or youth:ti,ab,kw or youths:ti,ab,kw or "young people":ti,ab,kw or 
pediatric*:ti,ab,kw or paediatric*:ti,ab,kw from 1992 to 2013, in Trials  
#10 #8 and #9 from 1992 to 2013, in Trials  
#11 counsel*:ti,ab,kw or advice:ti,ab,kw or advise*:ti,ab,kw from 1992 to 2013, in Trials  
#12 behavio*:ti,ab,kw and chang*:ti,ab,kw from 1992 to 2013, in Trials  
#13 behavio*:ti,ab,kw and intervention*:ti,ab,kw from 1992 to 2013, in Trials  
#14 behavio*:ti,ab,kw and modification*:ti,ab,kw from 1992 to 2013, in Trials  
#15 motivational next interview*:ti,ab,kw or cognitive next behavio*:ti,ab,kw from 1992 to 
2013, in Trials  
#16 behavio*:ti,ab,kw and therapy:ti,ab,kw from 1992 to 2013, in Trials  
#17 cbt:ti,ab,kw or brief next intervention*:ti,ab,kw or computer next based:ti,ab,kw or "self 
help":ti,ab,kw from 1992 to 2013, in Trials  
#18 email*:ti,ab,kw or internet:ti,ab,kw or text next messag*:ti,ab,kw or web:ti,ab,kw or 
website:ti,ab,kw from 1992 to 2013, in Trials  
#19 "patient education":ti,ab,kw or "health education":ti,ab,kw or "health promotion":ti,ab,kw 
from 1992 to 2013, in Trials  
#20 intervention*:ti or prevention:ti or preventive:ti or psychosocial:ti from 1992 to 2013, in 
Trials  
#21 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 from 1992 to 2013, in 
Trials  
#22 #10 and #21 from 1992 to 2013, in Trials 
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Category Included Excluded 
Aim Preventing and/or reducing drug use is a primary 
aim with or without addressing other substances 
or behaviors (e.g., addressing drug use and 
alcohol and tobacco use, addressing drug use  
and risky sexual behaviors) 
Targeting another behavior is only aim (e.g., 
alcohol misuse, tobacco use) (i.e., change in drug 
use is not a stated aim but is reported outcome) 
Condition Children or adolescents who are at the following 
stages of use: 1) never use, 2) experimentation,  
3) regular use, or 4) problem use.  
 
Use of the following drugs: 
 Cannabinoids (marijuana, hashish*, synthetic 
marijuana) 
 Prescription drugs for nonmedical purposes* 
(opioid pain relievers, CNS depressants, 
stimulants)  
 Stimulants (cocaine, amphetamine*, 
methamphetamine*) 
 Opioids (heroin, opium*) 
 Club drugs* (MDMA [ecstasy], flunitrazepam, 
GHB) 
 Dissociative drugs* (ketamine, PCP and 
analogs, Salvia divinorum, DXM) 
 Hallucinogens* (LSD [acid], mescaline, 
Psilocybin) 
 Inhalants* (also known as volatile substances) 
 Other emerging drugs* (Salvia, bath salts) 
 Use of over-the-counter drugs for psychoactive 
purposes (e.g., cough and cold medicines,  
 sleep aids) 
 Combination of the above drugs 
 Diagnosis of drug abuse or dependence (DSM-
IV-TR) or drug use disorder (DSM V) (studies of 
children and adolescents narratively described  
 as “substance abusing” will be included) 
 Medical use of drugs as prescribed 
 Nonpsychoactive drugs (e.g., anabolic steroids, 
laxatives, aspirin) 
 
Population  Children and adolescents (age ≤18 years) 
(includes studies in which >50% of participants 
are ≤18 years or subgroup of participants age 
≤18 years are analyzed and reported separately 
from adults), including trials limited to targeted 
groups with cognitive, mental health, or other 
health issues and trials limited to pregnant 
adolescents 
 Adults (age >18), unless adolescent subgroup 
results reported separately from adult results 
 Treatment-seeking children or adolescents  
 Children and adolescents who are referred to 
treatment by juvenile justice system, social or 
health agency, parents, or otherwise directly 
referred for substance abuse treatment in 
specialty settings 
 Trials in which ≥50% of the sample have severe 
mental health issues, such as schizophrenia, 
bipolar disorder, major depression, or acute 
psychosis 
 Trials in which ≥50% of the sample are 
diagnosed as having drug abuse or dependence 
(DSM-IV-TR) or a drug use disorder (DSM V) 
 Trials limited to other groups not generalizable to 
primary care: psychiatric inpatients, individuals in 
juvenile detention centers, court-mandated, 
juvenile offenders  
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Category Included Excluded 
Interventions Primary care–relevant behavioral counseling 
interventions designed primarily to prevent or 
reduce the nonmedical use of drugs with or 
without referral. Including, but not limited to:  
advice, brief intervention†, motivational 
interviewing, action plans, written materials, and 
personalized feedback. 
 
Conducted in primary care (i.e., office-based) or 
judged to be feasible or applicable to primary 
care:  
 Whom targeted: Individual-level identification 
 Who delivered: Usually involves primary care 
staff (primary care clinicians [e.g., family 
medicine, internal medicine, pediatrics], nurses, 
nurse practitioners, physician assistants, or 
related clinical staff [e.g., social workers, health 
educators, other counselors]) in some direct or 
indirect way or is seen as connected to the 
health care system by participant 
 How delivered: To individuals or in small 
groups (≤15). Generally involves no more than 8 
group sessions total, and intervention time 
period is no longer than 12 months  
 Where delivered: Located anywhere, as long 
as linked to health care (e.g., clinic, research 
setting, community, home, or interactive 
technologies [e.g., Web, text]) or primary care 
referable, such that the intervention is 
conducted as part of a health care setting or is 
widely available in the community (i.e., open 
enrollment) 
 Detoxification, medically managed withdrawal, 
or opioid substitution therapy (methadone 
maintenance programs) 
 Maintaining abstinence after substance use 
treatment for abuse or dependence (i.e., 
secondary abstinence) 
 Broad public health, media, or policy 
interventions 
 Trials within closed (pre-existing) social 
networks (e.g., worksites, churches, schools) 
 Inpatient/residential treatment (short- or long-
term) 
 Contingency management/vouchers 
 Vocational rehabilitation/Customized 
Employment Supports (CES) 
 Outward Bound/life skills training 
 Payer-level interventions aimed at influencing 
patient utilization 
 
 
Comparators  No intervention 
 Usual care 
 Waitlist 
 Attention control (e.g., similar in format and 
intensity, but intervention on a different content 
area) 
 Minimal intervention (no more than 1 single brief 
contact [i.e., <5 minutes] per year or brief written 
materials such as pamphlets)  
Active intervention (i.e., more than a single brief 
contact per year or brief written materials); 
comparative effectiveness  
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Category Included Excluded 
Outcomes KQ 1: Health, Social, Educational, and Other 
Outcomes 
Health Outcomes: 
 All-cause mortality 
 Drug-related mortality (intentional and 
unintentional) 
 Drug-related morbidity (including, but not limited 
to: mental health disorders; STI/HIV 
transmission; hepatitis B or C transmission; 
unintended pregnancy/pregnancy complications; 
respiratory infections; cardiovascular 
complications; stroke; seizures) 
 Drug-related injury or accidents 
 Other risky behaviors (e.g., alcohol, tobacco, 
other drug use; risky sexual behaviors) 
 Nonfatal overdose 
 Quality of life 
 Other related health outcome 
 
Social, Educational, or Other Outcomes: 
 Health care utilization 
 Global functioning 
 Educational attainment/school performance 
 Social/legal outcomes (e.g., incarcerations, out-
of-home juvenile placements, criminal activity, 
violence, drugged driving) 
 Family functioning 
 Other related social or educational outcome 
 
KQ 2: Behavioral Outcomes 
(Based on self-report or toxicology screen; will 
favor outcomes with biochemical verification) 
 No use 
 Frequency of use 
 Quantity of use 
 
KQ 3: Adverse Events 
 Serious treatment-related harms at any time 
point after the intervention began (e.g., death, 
including suicide, seizure, cardiovascular event, 
or other medical issue requiring urgent medical 
treatment) 
 Paradoxical increase in drug use 
 Demoralization due to failed quit attempt  
 Attitudes, knowledge, beliefs related to drug use 
 Intentions to change behavior 
 Intervention participation/compliance 
Outcome 
assessment 
timing 
≥6-month followup postbaseline assessment (26 
weeks)  
(Note: Studies with shorter followup will not be 
excluded at the title/abstract review phase so that 
we can evaluate how many total studies would be 
excluded for this reason only)  
<6-month followup postbaseline assessment 
Setting  Primary care settings  
 Emergency departments 
 Other settings included if study is linked to 
primary care or other health care, including: 
research clinics/offices, community centers, 
homes, and virtual (e.g., online support groups)  
 Substance abuse treatment centers 
 School classrooms 
 Worksites 
 Inpatient/residential 
 Other institutions (e.g., juvenile detention 
facilities) 
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Category Included Excluded 
Study 
Design 
KQs 1–3:  
 RCTs 
 Cluster-randomized controlled trials 
 Nonrandomized controlled trials (CCTs) 
KQs 1–3:  
 Prospective or retrospective cohort studies 
 Case-control studies 
 Time series studies 
 Before-after studies 
 Cross-sectional studies 
 Editorials, commentaries, case study, case 
series 
Study 
geography 
Developed countries, rated “Very High” according 
to the 2011 Human Development Index 
(http://hdr.undp.org/en/statistics): Andorra, 
Argentina, Australia, Austria, Bahrain, Barbados, 
Belgium, Brunei Darussalam, Canada, Chile, 
Croatia, Cyprus, Czech Republic, Denmark, 
Estonia, Finland, France, Germany, Greece, Hong 
Kong, China (SAR), Hungary, Iceland, Ireland, 
Israel, Italy, Japan, Korea (Republic of, Latvia, 
Liechtenstein, Lithuania, Luxembourg, Malta, 
Netherlands, New Zealand, Norway, Poland, 
Portugal, Qatar, Singapore, Slovakia, Slovenia, 
Spain, Sweden, Switzerland, United Arab 
Emirates, United Kingdom, United States 
Countries with a Human Development Index below 
“Very High” 
Publication 
language 
English Any language other than English 
Publication 
date 
1992 to present Studies published before 1992 
Quality rating Fair or good quality Poor quality 
*Not included in 2008 review.  
†Brief Intervention: typically delivered to those individuals at low to moderate risk. Goal is to provide education or 
advice, increase motivation to avoid substance use, or to teach behavior change skills that will reduce substance use 
as well as the chances of negative consequences. Usually involves 1 to 2 sessions that each last 5 minutes to 1 hour. 
 
Abbreviations: CNS = central nervous system; DSM = Diagnostic and Statistical Manual of Mental Disorders; DXM 
= dextromethorphan; GHB = gamma-hydroxybutyrate; KQ = Key Question, LSD = lysergic acid diethylamine; MDMA 
= methylenedioxy-methamphetamine; PCP = phencyclidine. 
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Criteria Good Rating Fair Rating Poor Rating 
Initial assembly of comparable groups 
(adequate randomization, including first 
concealment and whether potential 
confounders were distributed equally 
among groups) 
Met all criteria: Comparable groups 
were assembled initially and 
maintained throughout the study 
(overall followup at least 90% and 
difference in followup between groups 
no greater than 10 percentage points); 
reliable and valid measurement 
instruments were used and applied 
equally to the groups; interventions 
were spelled out clearly; all important 
outcomes were considered; and 
appropriate attention to confounders in 
analysis; participants were analyzed in 
the groups to which they were 
randomized. Conservative data 
substitution methods were used, such 
as baseline observation carried forward 
or multiple imputation, where data 
substitution is used. 
Studies were graded "fair" if any or all  
of the following problems occurred, 
without the fatal flaws noted in the 
"poor" category: Generally comparable 
groups were assembled initially but 
some question remained whether some 
(although not major) differences 
occurred with followup; measurement 
instruments were acceptable (although 
not the best) and generally applied 
equally; some but not all important 
outcomes were considered; and some 
but not all potential confounders were 
accounted for. Participants were 
analyzed in the groups to which they 
were randomized. 
Studies were graded "poor" if any of 
the following fatal flaws existed: 
Groups assembled initially were not 
close to being comparable or 
maintained throughout the study; 
unreliable or invalid measurement 
instruments were used or not applied 
at all equally among groups (including 
not masking outcome assessment); 
key confounders were given little or no 
attention; or participants were analyzed 
according to intervention received, 
rather than an intention-to-treat 
approach. 
Maintenance of comparable groups 
(includes attrition, cross-overs, 
adherence, contamination) 
Important differential loss to followup  
or overall high loss to followup 
Equal, reliable, and valid 
measurements (includes masking of 
outcome assessment) 
Clear definition of interventions 
All important outcomes considered 
Analysis (analyzed according to 
randomization status [intention-to-treat] 
rather than intervention received) 
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Exclusion code key 
E1. Geography: Not a country with a very high Human Development Index ranking 
E2a. Setting: Excluded on the basis of setting alone (e.g., substance abuse treatment centers, school 
classrooms, worksites, inpatient/residential, other institutions [e.g., juvenile detention facilities]) 
E2b. Setting: Setting potentially applicable to primary care but not directly or indirectly linked to health care 
or widely available in community to refer to (e.g., research clinic, community centers, homes, virtual) 
E3. Comparative effectiveness (control group received active intervention) 
E4. No relevant outcomes 
E5a. Population: Adults (age >18 years) or average age of study sample >18 years (unless age <18 years 
subgroup reported) 
E5b. Population: Treatment-seeking children or adolescents or mandated treatment 
E5c. Population: Psychiatric inpatients, individuals in juvenile detention centers, court-mandated, juvenile 
offenders 
E6a. Condition: >50% of children or adolescents in trial have drug abuse/dependence or drug use disorder 
E6b. Condition: Nonpsychoactive drugs 
E7a. Intervention: Not a primary care–relevant behavioral counseling intervention 
E7b. Intervention: Drug misuse is not a primary target of the intervention 
E8. Study design: Not a randomized, controlled trial or clinical controlled trial 
E9. Followup: <6 months (24 weeks) followup postbaseline (does not apply to harms) 
E10. Study relevance 
E11. Poor-quality rating 
 
1.  Aalborg AE, Miller BA, Husson G, et al. 
Implementation of adolescent family-based 
substance use prevention programs in health 
care settings: comparisons across conditions 
and programs. Health Educ J 2012 Jan 
1;71(1):53-61. PMID: 22984294. KQ1E4, 
KQ2E4, KQ3E4. 
2.  Baer JS, Peterson PL, Wells EA, et al. Brief 
intervention for drug use with homeless 
adolescents: a preliminary report. 
Proceedings of the 67th Annual Scientific 
Meeting of the College on Problems of Drug 
Dependence.  2005 Jun 19; Orlando, FL. 
2005. PMID: None. KQ1E2a, KQ2E2a, 
KQ3E2a. 
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Behav 2007 Dec;21(4):582-6. PMID: 
18072842. KQ1E9, KQ2E9, KQ3E9. 
4.  Bailey KA, Baker AL, Webster RA, et al. 
Pilot randomized controlled trial of a brief 
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Drug Alcohol Rev 2004 Jun;23(2):157-66. 
PMID: 15370021. KQ1E10, KQ2E10, 
KQ3E10. 
5.  Barlow A, Mullany B, Neault N, et al. Effect 
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6.  Battjes RJ, Gordon MS, O'Grady KE, et al. 
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Abuse Treat 2004;27:123-34. PMID: 
15450645. KQ1E5b, KQ2E5b, KQ3E5b. 
7.  Behrendt S, Wittchen HU, Hofler M, et al. 
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escalation? Drug Alcohol Depend 2009 Jan 
1;99(1-3):68-78. PMID: 18768267. 
KQ1E10, KQ2E10, KQ3E10. 
8.  Bernat DH, August GJ, Hektner JM, et al. 
The Early Risers preventive intervention: 
testing for six-year outcomes and 
mediational processes. J Abnorm Child 
Psychol 2007 Aug;35(4):605-17. PMID: 
17333359. KQ1E2a, KQ2E2a, KQ3E2a. 
9.  Bernstein E, Edwards E, Dorfman D, et al. 
Screening and brief intervention to reduce 
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Acad Emerg Med 2009 Nov;16(11):1174-
85. PMID: 20053238. KQ1E5a, KQ2E5a, 
KQ3E5a. 
10.  Bohnert KM, Walton MA, Barry K, et al. 
Three-month efficacy of a brief intervention 
for reducing marijuana use and 
consequences among adolescents presenting 
to indigent primary care clinics. Proceedings 
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College on Problems of Drug Dependence.  
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12.  Bonsack C, Gibellini MS, Favrod J, et al. 
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18.  Burleson JA, Kaminer Y, Dennis ML. 
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Am J Addict 2006;15:Suppl-15. PMID: 
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substance use disorders: a pilot study. Cultur 
Divers Ethnic Minor Psychol 2012 
Oct;18(4):373-83. PMID: 22866693. 
KQ1E5c, KQ2E5c, KQ3E5c. 
20.  Catalano RF, Gainey RR, Fleming CB, et al. 
An experimental intervention with families 
of substance abusers: one-year follow-up of 
the focus on families project. Addiction 
1999 Feb;94(2):241-54. PMID: 10396792. 
KQ1E7a, KQ2E7a, KQ3E7a. 
21.  Comulada WS, Weiss RE, Cumberland W, 
et al. Reductions in drug use among young 
people living with HIV. Am J Drug Alcohol 
Abuse 2007;33(3):493-501. PMID: 
17613977. KQ1E5a, KQ2E5a, KQ3E5a. 
22.  Connell AM, Dishion TJ, Deater-Deckard 
K. Variable- and person-centered 
approaches to the analysis of early 
adolescent substance use: linking peer, 
family, and intervention effects with 
developmental trajectories. Merrill-Palmer 
Quarterly 2006;52(3):421-48. PMID: None. 
KQ1E2a, KQ2E2a, KQ3E2a. 
23.  Conrod PJ, Castellanos-Ryan N, Strang J. 
Brief, personality-targeted coping skills 
interventions and survival as a non-drug user 
over a 2-year period during adolescence. 
Arch Gen Psychiatry 2010 Jan;67(1):85-93. 
PMID: 20048226. KQ1E2a, KQ2E2a, 
KQ3E2a. 
24.  Corby EA, Russell JC. Substance abuse risk 
reduction: verbal mediational training for 
children by parental and nonparental 
models. Subst Abuse 1997;18(4):145-64. 
PMID: None. KQ1E2a, KQ2E2a, 
KQ3E2a. 
25.  Cordova D, Huang S, Pantin H, et al. Do the 
effects of a family intervention on alcohol 
and drug use vary by nativity status? 
Psychol Addict Behav 2012 Sep;26(3):655-
60. PMID: 22141423. KQ1E2b, KQ2E2b, 
KQ3E2b. 
26.  Correia CJ, Benson TA, Carey KB. 
Decreased substance use following increases 
in alternative behaviors: a preliminary 
investigation. Addict Behav 2005;30:19-27. 
PMID: 15561446. KQ1E2a, KQ2E2a, 
KQ3E2a. 
27.  D'Amico EJ, Fromme K. Brief prevention 
for adolescent risk-taking behavior. 
Addiction 2002 May;97(5):563-74. PMID: 
12033657. KQ1E2a, KQ2E2a, KQ3E2a. 
28.  D'Amico EJ, Miles JN, Stern SA, et al. Brief 
motivational interviewing for teens at risk of 
substance use consequences: a randomized 
pilot study in a primary care clinic. J Subst 
Abuse Treat 2008 Jul;35(1):53-61. PMID: 
18037603. KQ1E9, KQ2E9, KQ3E9. 
Drug Misuse in Children and Adolescents 61  Kaiser Permanente Research Affiliates EPC 
Appendix B. Excluded Studies 
29.  Danielson CK, McCart MR, Walsh K, et al. 
Reducing substance use risk and mental 
health problems among sexually assaulted 
adolescents: a pilot randomized controlled 
trial. J Fam Psychol 2012 Aug;26(4):628-35. 
PMID: 22686269. KQ1E2b, KQ2E2b, 
KQ3E2b. 
30.  Edwards J, Elkins K, Hinton M, et al. 
Randomized controlled trial of a cannabis-
focused intervention for young people with 
first-episode psychosis. Acta Psychiatr 
Scand 2006 Aug;114(2):109-17. PMID: 
16836598.  KQ1E5a, KQ2E5a, KQ3E5a. 
31.  Erickson SJ, Gerstle M, Feldstein SW. Brief 
interventions and motivational interviewing 
with children, adolescents, and their parents 
in pediatric health care settings: a review. 
Arch Pediatr Adolesc Med 2005 
Dec;159(12):1173-80. PMID: 16330743. 
KQ1E8, KQ2E8, KQ3E8. 
32.  Fang L, Schinke SP, Cole KC. Preventing 
substance use among early Asian-American 
adolescent girls: initial evaluation of a web-
based, mother-daughter program. J Adolesc 
Health 2010 Nov;47(5):529-32. PMID: 
20970090. KQ3E4. 
33.  Fang L, Schinke SP. Two-year outcomes of 
a randomized, family-based substance use 
prevention trial for Asian American 
adolescent girls. Psychol Addict Behav 2012 
Dec 31 PMID: 23276322. KQ3E4. 
34.  Fischer B, Dawe M, McGuire F, et al. 
Feasibility and impact of brief interventions 
for frequent cannabis users in Canada. J 
Subst Abuse Treat 2013 Jan;44(1):132-8. 
PMID: 22520278. KQ1E5a, KQ2E5a, 
KQ3E5a. 
35.  Fors SW, Jarvis S. Evaluation of a peer-led 
drug abuse risk reduction project for 
runaway/homeless youths. J Drug Educ 
1995;25(4):321-33. PMID: 8907403. 
KQ1E4, KQ2E4, KQ3E4. 
36.  Garfein RS, Golub ET, Greenberg AE, et al. 
A peer-education intervention to reduce 
injection risk behaviors for HIV and 
hepatitis C virus infection in young injection 
drug users. AIDS 2007 Sep 12;21(14):1923-
32. PMID: 17721100. KQ1E4, KQ2E4, 
KQ3E4. 
37.  Gonzales NA, Dumka LE, Millsap RE, et al. 
Randomized trial of a broad preventive 
intervention for Mexican American 
adolescents. J Consult Clin Psychol 2012 
Feb;80(1):1-16. PMID: 22103956. 
KQ1E2b, KQ2E2b, KQ3E2b. 
38.  Goti J, Diaz R, Serrano L, et al. Brief 
intervention in substance-use among 
adolescent psychiatric patients: a 
randomized controlled trial. Eur Child 
Adolesc Psychiatry 2010 Jun;19(6):503-11. 
PMID: 19779855. KQ1E9, KQ2E9, 
KQ3E9. 
39.  Gray E, McCambridge J, Strang J. The 
effectiveness of motivational interviewing 
delivered by youth workers in reducing 
drinking, cigarette and cannabis smoking 
among young people: quasi-experimental 
pilot study. Alcohol Alcohol 2005 
Nov;40(6):535-9. PMID: 16131498. 
KQ1E2a, KQ2E2a, KQ3E2a. 
40.  Griffin KW, Samuolis J, Williams C. 
Efficacy of a self-administered home-based 
parent intervention on parenting behaviors 
for preventing adolescent substance use. J 
Child Family Stud 2011;20(3):319-25. 
PMID: None. KQ1E4, KQ2E4, KQ3E4. 
41.  Gross J, McCaul ME. An evaluation of a 
psychoeducational and substance abuse risk 
reduction intervention for children of 
substance-abusers. J Community Psychol 
1992:75-87. PMID: None. KQ1E8, 
KQ2E8, KQ3E8. 
42.  Haggerty KP, Skinner ML, MacKenzie EP, 
et al. A randomized trial of Parents Who 
Care: effects on key outcomes at 24-month 
follow-up. Prev Sci 2007 Dec;8(4):249-60. 
PMID: 17987388. KQ1E3, KQ2E3, 
KQ3E3. 
43.  Haggerty KP, Skinner M, Fleming CB, et al. 
Long-term effects of the Focus on Families 
project on substance use disorders among 
children of parents in methadone treatment. 
Addiction 2008 Dec;103(12):2008-16. 
PMID: 18855808. KQ1E7a, KQ2E7a, 
KQ3E7a. 
44.  Harris SK, Csemy L, Sherritt L, et al. 
Computer-facilitated substance use 
screening and brief advice for teens in 
primary care: an international trial. 
Pediatrics 2012 Jun;129(6):1072-82. PMID: 
22566420. KQ1E4, KQ3E4. 
45.  Henderson CE, Rowe CL, Dakof GA, et al. 
Parenting practices as mediators of 
treatment effects in an early-intervention 
trial of multidimensional family therapy. 
Am J Drug Alcohol Abuse 2009;35(4):220-
6. PMID: 20180674. KQ1E3, KQ2E3, 
KQ3E3. 
Drug Misuse in Children and Adolescents 62  Kaiser Permanente Research Affiliates EPC 
Appendix B. Excluded Studies 
46.  Hides L, Carroll S, Scott R, et al. Quik Fix: 
a randomized controlled trial of an enhanced 
brief motivational interviewing intervention 
for alcohol/cannabis and psychological 
distress in young people. Psychother 
Psychosom 2013;82(2):122-4. PMID: 
23295899. KQ1E3, KQ2E3, KQ3E3. 
47.  Hollen PJ, Tyc VL, Donnangelo SF, et al. A 
use decision aid for medically at-risk 
adolescents: results of a randomized 
controlled trial for cancer-surviving 
adolescents. Cancer Nurs 2013 Jan 25 
PMID: 23357887. KQ1E4, KQ2E4, 
KQ3E4. 
48.  Horigian VE, Robbins MS, Dominguez R, et 
al. Principles for defining adverse events in 
behavioral intervention research: lessons 
from a family-focused adolescent drug 
abuse trial. Clin Trials 2010 Feb;7(1):58-68. 
PMID: 20156957. KQ1E4, KQ2E4, 
KQ3E4. 
49.  Humeniuk R, Ali R, Babor T, et al. A 
randomized controlled trial of a brief 
intervention for illicit drugs linked to the 
Alcohol, Smoking and Substance 
Involvement Screening Test (ASSIST) in 
clients recruited from primary health-care 
settings in four countries. Addiction 2012 
May;107(5):957-66. PMID: 22126102. 
KQ1E5a, KQ2E5a, KQ3E5a. 
50.  Kaminer Y, Burleson JA, Blitz C, et al. 
Psychotherapies for adolescent substance 
abusers: a pilot study. J Nerv Ment Dis 1998 
Nov;186(11):684-90. PMID: 9824170. 
KQ1E6a, KQ2E6a, KQ3E6a. 
51.  Kaminer Y, Burleson JA. Psychotherapies 
for adolescent substance abusers: 15-month 
follow-up of a pilot study. Am J Addict 
1999;8(2):114-9. PMID: 10365191. 
KQ1E6a, KQ2E6a, KQ3E6a. 
52.  Kaminer Y, Burleson JA, Goldberger R. 
Cognitive-behavioral coping skills and 
psychoeducation therapies for adolescent 
substance abuse. J Nerv Ment Dis 2002 
Nov;190(11):737-45. PMID: 12436013. 
KQ1E5b, KQ2E5b, KQ3E5b. 
53.  Kamon J, Budney A, Stanger C. A 
contingency management intervention for 
adolescent marijuana abuse and conduct 
problems. J Amer Acad Child Adolesc 
Psychiatry 2005 Jun;44(6):513-21. PMID: 
15908833. KQ1E8, KQ2E8, KQ3E8. 
54.  Kemp R, Harris A, Vurel E, et al. Stop 
Using Stuff: trial of a drug and alcohol 
intervention for young people with 
comorbid mental illness and drug and 
alcohol problems. Australas Psychiatry 2007 
Dec;15(6):490-3. PMID: 17852064. 
KQ1E5a, KQ2E5a, KQ3E5a. 
55.  Kim HK, Leve LD. Substance use and 
delinquency among middle school girls in 
foster care: a three-year follow-up of a 
randomized controlled trial. J Consult Clin 
Psychol 2011 Dec;79(6):740-50. PMID: 
22004305. KQ1E2b, KQ2E2b, KQ3E2b. 
56.  Knight JR, Sherritt L, Van HS, et al. 
Motivational interviewing for adolescent 
substance use: a pilot study. J Adolesc 
Health 2005 Aug;37(2):167-9. PMID: 
16026730. KQ1E8, KQ2E8, KQ3E8. 
57.  Koniak-Griffin D, Anderson NL, 
Verzemnieks I, et al. A public health nursing 
early intervention program for adolescent 
mothers: outcomes from pregnancy through 
6 weeks postpartum. Nurs Res 2000 
May;49(3):130-8. PMID: 10882317. 
KQ1E10, KQ2E10, KQ3E10. 
58.  Kumpfer KL, Whiteside HO, Greene JA, et 
al. Effectiveness outcomes of four age 
versions of the Strengthening Families 
Program in statewide field sites. Group Dyn 
2010;14(3):211-29. KQ1E2a, KQ2E2a, 
KQ3E2a. 
59.  Latimer WW, Winters KC, D'Zurilla T, et 
al. Integrated family and cognitive-
behavioral therapy for adolescent substance 
abusers: a stage I efficacy study. Drug 
Alcohol Depend 2003 Sep 10;71(3):303-17. 
PMID: 12957348. KQ1E3, KQ2E3, 
KQ3E3. 
60.  Lecallier D, Hadj SF, Landry M, et al. 
Screening, referring and counseling of 
adolescents for substance abuse. A 
randomized controlled study on 2120 
students: Reperer, orienter, conseiller les 
adolescents consommateurs de substances 
psycho-actives (ROC-ADO). etude 
prospective randomisee controlee aupres de 
2120 adolescents. Presse Med 
2012;41:e411-e419. PMID: 22445839. 
KQ1E12, KQ2E12, KQ3E12. 
61.  Lee CM, Neighbors C, Kilmer JR, et al. A 
brief, web-based personalized feedback 
selective intervention for college student 
marijuana use: a randomized clinical trial. 
Psychol Addict Behav 2010 Jun;24(2):265-
73. PMID: 20565152. KQ1E2a, KQ2E2a, 
KQ3E2a. 
Drug Misuse in Children and Adolescents 63  Kaiser Permanente Research Affiliates EPC 
Appendix B. Excluded Studies 
62.  Liddle HA, Dakof GA, Turner RM, et al. 
Treating adolescent drug abuse: a 
randomized trial comparing 
multidimensional family therapy and 
cognitive behavior therapy. Addiction 2008 
Oct;103(10):1660-70. PMID: 18705691. 
KQ1E6a, KQ2E6a, KQ3E6a. 
63.  Liddle HA, Dakof GA, Parker K, et al. 
Multidimiensional family therapy for 
adolescent drug abuse: Results of a 
randomized clinical trial. Am J Drug 
Alcohol Abuse 2001;27(4):651-88. PMID: 
11727882. KQ1E5b, KQ2E5b, KQ3E5b. 
64.  Lochman JE, Wells KC. The Coping Power 
program at the middle-school transition: 
universal and indicated prevention effects. 
Psychol Addict Behaviors 2002 
Dec;16(4:Suppl):Suppl-54. PMID: 
12502276. KQ1E2a, KQ2E2a, KQ3E2a. 
65.  Lord SE, D'Amante D, Clements K, et al. 
Efficacy of an online substance abuse 
prevention program for early adolescents. 
Proceedings of the 70th Annual Scientific 
Meeting of the College on Problems of Drug 
Dependence.  2008 Jun 14; San Juan, Puerto 
Rico. 2008. p. 116. PMID: None. KQ1E4, 
KQ2E4, KQ3E4. 
66.  Mackesy-Amiti ME, Ouellet LJ, Golub ET, 
et al. Predictors and correlates of reduced 
frequency or cessation of injection drug use 
during a randomized HIV prevention 
intervention trial. Addiction 2011 
Mar;106(3):601-8. PMID: 21182555. 
KQ1E5a, KQ2E5a, KQ3E5a. 
67.  Marsden J, Stillwell G, Barlow H, et al. An 
evaluation of a brief motivational 
intervention among young ecstasy and 
cocaine users: no effect on substance and 
alcohol use outcomes. Addiction 2006 
Jul;101(7):1014-26. PMID: 16771893. 
KQ1E2b, KQ2E2b, KQ3E2b. 
68.  Marsden J, Stillwell G, Barlow H, et al. An 
evaluation of a brief intervention model for 
use with young non-injecting stimulant 
users. Drugs 2005;12(Suppl1):90-3. PMID: 
None. KQ1E2b, KQ2E2b, KQ3E2b. 
69.  Martin G, Copeland J. The adolescent 
cannabis check-up: randomized trial of a 
brief intervention for young cannabis users. 
J Subst Abuse Treat 2008 Jun;34(4):407-14. 
PMID: 17869051. KQ1E3, KQ2E3, 
KQ3E3. 
70.  Martinez CR, Jr., Eddy JM. Effects of 
culturally adapted parent management 
training on Latino youth behavioral health 
outcomes. J Consult Clin Psychol 2005 
Oct;73(5):841-51. PMID: 16287384. 
KQ1E4, KQ2E4, KQ3E4. 
71.  Mason M, Pate P, Drapkin M, et al. 
Motivational interviewing integrated with 
social network counseling for female 
adolescents: a randomized pilot study in 
urban primary care. J Subst Abuse Treat 
2011 Sep;41(2):148-55. PMID: 21489741. 
KQ1E9, KQ2E9, KQ3E9. 
72.  Mason WA, Kosterman R, Hawkins JD, et 
al. Influence of a family-focused substance 
use preventive intervention on growth in 
adolescent depressive symptoms. J Res 
Adolesc 2007;17(3):541-64. PMID: None. 
KQ1E2b, KQ2E2b, KQ3E2b. 
73.  Mason WA, Haggerty KP, Fleming AP, et 
al. Family intervention to prevent depression 
and substance use among adolescents of 
depressed parents. J Child Fam Stud 
2012;21(6):891-905. PMID: None. 
KQ1E2b, KQ2E2b, KQ3E2b. 
74.  McCambridge J, Strang J. The efficacy of 
single-session motivational interviewing in 
reducing drug consumption and perceptions 
of drug-related risk and harm among young 
people: results from a multi-site cluster 
randomized trial. Addiction 2004 
Jan;99(1):39-52. PMID: 14678061. 
KQ1E2a, KQ2E2a, KQ3E2a. 
75.  McCambridge J, Strang J. Deterioration 
over time in effect of Motivational 
Interviewing in reducing drug consumption 
and related risk among young people. 
Addiction 2005 Apr;100(4):470-8. PMID: 
15784061. KQ1E2a, KQ2E2a, KQ3E2a. 
76.  McCambridge J, Slym RL, Strang J. 
Randomized controlled trial of motivational 
interviewing compared with drug 
information and advice for early 
intervention among young cannabis users. 
Addiction 2008 Nov;103(11):1809-18. 
PMID: 18778385. KQ1E3, KQ2E3, 
KQ3E3. 
77.  McCambridge J, Day M, Thomas BA, et al. 
Fidelity to Motivational Interviewing and 
subsequent cannabis cessation among 
adolescents. Addict Behav 2011 
Jul;36(7):749-54. PMID: 21440994. 
KQ1E9, KQ2E9, KQ3E9. 
Drug Misuse in Children and Adolescents 64  Kaiser Permanente Research Affiliates EPC 
Appendix B. Excluded Studies 
78.  McCambridge J, Hunt C, Jenkins RJ, et al. 
Cluster randomised trial of the effectiveness 
of motivational interviewing for universal 
prevention. Drug Alcohol Depend 2011 Apr 
1;114(2-3):177-84. PMID: 21075562. 
KQ1E2a, KQ2E2a, KQ3E2a. 
79.  McGillicuddy NB, Rychtarik RG, Duquette 
JA, et al. Development of a skill training 
program for parents of substance-abusing 
adolescents. J Subst Abuse Treat 2001 
Jan;20(1):59-68. PMID: 11239729. KQ1E9, 
KQ2E9, KQ3E9. 
80.  Milburn NG, Iribarren FJ, Rice E, et al. A 
family intervention to reduce sexual risk 
behavior, substance use, and delinquency 
among newly homeless youth. J Adolesc 
Health 2012 Apr;50(4):358-64. PMID: 
22443839. KQ1E9, KQ2E9, KQ3E9. 
81.  Miller WR, Toscova RT, Miller JH, et al. A 
theory-based motivational approach for 
reducing alcohol/drug problems in college. 
Health Educ Behav 2000 Dec;27(6):744-59. 
PMID: 11104373. KQ1E2a, KQ2E2a, 
KQ3E2a. 
82.  Molina BS, Flory K, Hinshaw SP, et al. 
Delinquent behavior and emerging 
substance use in the MTA at 36 months: 
prevalence, course, and treatment effects. J 
Am Acad Child Adolesc Psychiatry 2007 
Aug;46(8):1028-40. PMID: 17667481. 
KQ1E8, KQ2E8, KQ3E8. 
83.  Morris J, Parker H, Aldridge J. The 
Integrated Programme: An evaluation of a 
multi-component drugs prevention 
programme in northern England (1996-
1999). Drugs 2002;9(2):153-68. PMID: 
None. KQ1E2a, KQ2E2a, KQ3E2a. 
84.  Mullany B, Barlow A, Neault N, et al. The 
Family Spirit Trial for American Indian teen 
mothers and their children: CBPR rationale, 
design, methods and baseline characteristics. 
Prev Sci 2012 Oct;13(5):504-18. PMID: 
None. KQ1E4, KQ2E4, KQ3E4. 
85.  Murphy DA, Chen X, Naar-King S, et al. 
Alcohol and marijuana use outcomes in the 
Healthy Choices motivational interviewing 
intervention for HIV-positive youth. Aids 
Patient Care STDS 2012 Feb;26(2):95-100. 
PMID: 22191456. KQ1E5a, KQ2E5a, 
KQ3E5a. 
86.  Murry VM, Berkel C, Chen YF, et al. 
Intervention induced changes on parenting 
practices, youth self-pride and sexual norms 
to reduce HIV-related behaviors among 
rural African American youths. J Youth 
Adolesc 2011 Sep;40(9):1147-63. PMID: 
21373904. KQ1E4, KQ2E4, KQ3E4. 
87.  Naar-King S, Wright K, Parsons JT, et al. 
Healthy choices: motivational enhancement 
therapy for health risk behaviors in HIV-
positive youth. AIDS Educ Prev 2006 
Feb;18(1):1-11. PMID: 16539572. 
KQ1E5a, KQ2E5a, KQ3E5a. 
88.  Naar-King S, Lam P, Wang B, et al. Brief 
report: maintenance of effects of 
motivational enhancement therapy to 
improve risk behaviors and HIV-related 
Health in a randomized controlled trial of 
youth living with HIV. J Pediatr Psychol 
2008 May;33(4):441-5. PMID: 17905800. 
KQ1E5a, KQ2E5a, KQ3E5a. 
89.  Naar-King S, Parsons JT, Murphy DA, et al. 
Improving health outcomes for youth living 
with the human immunodeficiency virus: a 
multisite randomized trial of a motivational 
intervention targeting multiple risk 
behaviors. Arch Pediatr Adolesc Med 2009 
Dec;163(12):1092-8. PMID: 19996045. 
KQ1E3, KQ2E3, KQ3E3. 
90.  Newton NC, Andrews G, Teesson M, et al. 
Delivering prevention for alcohol and 
cannabis using the Internet: a cluster 
randomised controlled trial. Prev Med 2009 
Jun;48(6):579-84. PMID: 19389420. 
KQ1E2a, KQ2E2a, KQ3E2a. 
91.  Nyamathi A, Branson C, Kennedy B, et al. 
Impact of nursing intervention on decreasing 
substances among homeless youth. Am J 
Addict 2012 Nov;21(6):558-65. PMID: 
23082836. KQ1E5a, KQ2E5a, KQ3E5a. 
92.  Oliansky DM, Wildenhaus KJ, Manlove K, 
et al. Effectiveness of brief interventions in 
reducing substance use among at-risk 
primary care patients in three community-
based clinics. Subst Abuse 1997;18(3):95-
103. PMID: None. KQ1E9, KQ2E9, 
KQ3E9. 
93.  Ozer EM, Adams SH, Orrell-Valente JK, et 
al. Does delivering preventive services in 
primary care reduce adolescent risky 
behavior? J Adolesc Health 2011 
Nov;49(5):476-82. PMID: 22018561. 
KQ1E8, KQ2E8, KQ3E8. 
94.  Palinkas LA, Atkins CJ, Miller C, et al. 
Social skills training for drug prevention in 
high-risk female adolescents. Prev Med 
1996 Nov;25(6):692-701. PMID: 8936571. 
KQ1E7a, KQ2E7a, KQ3E7a. 
Drug Misuse in Children and Adolescents 65  Kaiser Permanente Research Affiliates EPC 
Appendix B. Excluded Studies 
95.  Pantin H, Coatsworth JD, Feaster DJ, et al. 
Familias Unidas: the efficacy of an 
intervention to promote parental investment 
in Hispanic immigrant families. Prev Sci 
2003 Sep;4(3):189-201. PMID: 12940469. 
KQ1E4, KQ2E4, KQ3E4. 
96.  Pantin H, Prado G, Lopez B, et al. A 
randomized controlled trial of Familias 
Unidas for Hispanic adolescents with 
behavior problems. Psychosom Med 2009 
Nov;71(9):987-95. PMID: 19834053. 
KQ1E2b, KQ2E2b, KQ3E2b. 
97.  Peterson PL, Baer JS, Wells EA, et al. 
Short-term effects of a brief motivational 
intervention to reduce alcohol and drug risk 
among homeless adolescents. Psychol 
Addict Behav 2006 Sep;20(3):254-64. 
PMID: 16938063. KQ1E9, KQ2E9, 
KQ3E9. 
98.  Pierce JP, James LE, Messer K, et al. 
Telephone counseling to implement best 
parenting practices to prevent adolescent 
problem behaviors. Contemp Clin Trials 
2008;29(3):324-34. PMID: 17964223. 
KQ1E4, KQ2E4, KQ3E4. 
99.  Prado G, Pantin H, Briones E, et al. A 
randomized controlled trial of a parent-
centered intervention in preventing 
substance use and HIV risk behaviors in 
Hispanic adolescents. J Consult Clin 
Psychol 2007 Dec;75(6):914-26. PMID: 
18085908. KQ1E2b, KQ2E2b, KQ3E2b. 
100.  Ramchand R, Griffin BA, Suttorp M, et al. 
Using a cross-study design to assess the 
efficacy of motivational enhancement 
therapy-cognitive behavioral therapy 5 
(MET/CBT5) in treating adolescents with 
cannabis-related disorders. J Stud Alcohol 
Drugs 2011 May;72(3):380-9. PMID: 
21513674. KQ1E3, KQ2E3, KQ3E3. 
101.  Rhee H, Hollen PJ, Belyea MJ, et al. 
Decision-making program for rural 
adolescents with asthma: a pilot study. J 
Pediatr Nurs 2008 Dec;23(6):439-50. PMID: 
19026912. KQ1E4, KQ3E4. 
102.  Riesch SK, Brown RL, Anderson LS, et al. 
Strengthening families program (10-14): 
effects on the family environment. West J 
Nurs Res 2012 Apr;34(3):340-76. PMID: 
21403057. KQ1E2b, KQ2E2b, KQ3E2b. 
103.  Robbins MS, Szapocznik J, Horigian VE, et 
al. Brief strategic family therapy for 
adolescent drug abusers: a multi-site 
effectiveness study. Contemp Clin Trials 
2009;30:269-78. PMID: 19470315. 
KQ1E5b, KQ2E5b, KQ3E5b. 
104.  Rotheram-Borus MJ, Song J, Gwadz M, et 
al. Reductions in HIV risk among runaway 
youth. Prev Sci 2003 Sep;4(3):173-87. 
PMID: 12940468. KQ1E10, KQ2E10, 
KQ3E10. 
105.  Rotheram-Borus MJ, Swendeman D, 
Comulada WS, et al. Prevention for 
substance-using HIV-positive young people: 
telephone and in-person delivery. J Acquir 
Immune Defic Syndr 2004 Oct 1;37:Suppl-
77. PMID: 15385902. KQ1E5a, KQ2E5a, 
KQ3E5a. 
106.  Sarvela PD, Ford TD. Indicators of 
substance use among pregnant adolescents 
in the Mississippi Delta. J Sch Health 1992 
May;62(5):175-9. PMID: 1522698. KQ1E4, 
KQ2E4, KQ3E4. 
107.  Sarvela PD, Ford TD. An evaluation of a 
substance abuse education program for 
Mississippi delta pregnant adolescents. J Sch 
Health 1993 Mar;63(3):147-52. PMID: 
8487513. KQ1E11, KQ2E11, KQ3E11. 
108.  Schinke S, Schwinn T. Gender-specific 
computer-based intervention for preventing 
drug abuse among girls. Am J Drug Alcohol 
Abuse 2005;31(4):609-16. PMID: 
16320437. KQ1E9, KQ2E9, KQ3E9. 
109.  Schinke S, Di NJ, Schwinn T, et al. Drug 
abuse risk and protective factors among 
black urban adolescent girls: a group-
randomized trial of computer-delivered 
mother-daughter intervention. Psychol 
Addict Behav 2006 Dec;20(4):496-500. 
PMID: 17176186. KQ1E4, KQ2E4, 
KQ3E4. 
110.  Schinke SP, Schwinn TM, Di NJ, et al. 
Reducing the risks of alcohol use among 
urban youth: three-year effects of a 
computer-based intervention with and 
without parent involvement. J Stud Alcohol 
2004 Jul;65(4):443-9. PMID: 15376818. 
KQ1E10, KQ2E10, KQ3E10. 
111.  Schinke SP, Fang L, Cole KC. Preventing 
substance use among adolescent girls: 1-
year outcomes of a computerized, mother-
daughter program. Addict Behav 2009 
Dec;34(12):1060-4. PMID: 19632053. 
KQ3E4. 
112.  Schinke SP, Cole KC, Fang L. Gender-
specific intervention to reduce underage 
drinking among early adolescent girls: a test 
of a computer-mediated, mother-daughter 
program. J Stud Alcohol Drugs 2009 
Jan;70(1):70-7. PMID: 19118394. KQ1E4, 
KQ2E4, KQ3E4. 
Drug Misuse in Children and Adolescents 66  Kaiser Permanente Research Affiliates EPC 
Appendix B. Excluded Studies 
113.  Schinke SP, Fang L, Cole KC. Computer-
delivered, parent-involvement intervention 
to prevent substance use among adolescent 
girls. Prev Med 2009 Nov;49(5):429-35. 
PMID: 19682490. KQ3E4. 
114.  Schwinn TM, Schinke SP, Di NJ. 
Preventing drug abuse among adolescent 
girls: outcome data from an internet-based 
intervention. Prev Sci 2010 Mar;11(1):24-
32. PMID: 19728091. KQ1E2b, KQ2E2b, 
KQ3E2b. 
115.  Siegel JT, Alvaro EM, Crano WD, et al. 
Influencing inhalant intentions by changing 
socio-personal expectations. Prev Sci 2008 
Sep;9(3):153-65. PMID: 18543103. 
KQ1E2a, KQ2E2a, KQ3E2a. 
116.  Sinadinovic K, Wennberg P, Berman AH. 
Targeting problematic users of illicit drugs 
with internet-based screening and brief 
intervention: A randomized controlled trial. 
Drug Alcohol Depend 2012 Nov;126(1-
2):42-50. PMID: 22613182. KQ1E5a, 
KQ2E5a, KQ3E5a. 
117.  Slesnick N, Kang MJ. The impact of an 
integrated treatment on HIV risk behavior 
among homeless youth: a randomized 
controlled trial. J Behav Med 2008 
Feb;31(1):45-59. PMID: 17940861. 
KQ1E6a, KQ2E6a, KQ3E6a. 
118.  Smith DC, Hall JA, Williams JK, et al. 
Comparative efficacy of family and group 
treatment for adolescent substance abuse. 
Am J Addict 2006;15:Suppl-6. PMID: 
17182429. KQ1E3, KQ2E3, KQ3E3. 
119.  Smith DK, Chamberlain P, Eddy JM. 
Preliminary support for multidimensional 
treatment foster care in reducing substance 
use in delinquent boys. J Child Adolesc 
Subst Abuse 2010;19(4):343-58. PMID: 
20953309. KQ1E5c, KQ2E5c, KQ3E5c. 
120.  Srisurapanont M, Sombatmai S, 
Boripuntakul T. Brief intervention for 
students with methamphetamine use 
disorders: a randomized controlled trial. Am 
J Addict 2007 Mar;16(2):111-6. PMID: 
17453612. KQ1E1, KQ2E1, KQ3E1. 
121.  Stanger C, Budney AJ, Kamon JL, et al. A 
randomized trial of contingency 
management for adolescent marijuana abuse 
and dependence. Drug Alcohol Depend 
2009 Dec 1;105(3):240-7. PMID: 19717250. 
KQ1E5b, KQ2E5b, KQ3E5b. 
122.  Stern SA, Meredith LS, Gholson J, et al. 
Project CHAT: a brief motivational 
substance abuse intervention for teens in 
primary care. J Subst Abuse Treat 
2007;32(2):153-65. PMID: 17306724. 
KQ1E4, KQ2E4, KQ3E4. 
123.  Stormshak EA, Connell AM, Veronneau 
MH, et al. An ecological approach to 
promoting early adolescent mental health 
and social adaptation: family-centered 
intervention in public middle schools. Child 
Dev 2011 Jan;82(1):209-25. PMID: 
21291438. KQ1E2a, KQ2E2a, KQ3E2a. 
124.  Tait RJ, Hulse GK, Robertson SI. 
Effectiveness of a brief-intervention and 
continuity of care in enhancing attendance 
for treatment by adolescent substance users. 
Drug Alcohol Depend 2004 Jun 
11;74(3):289-96. PMID: 15194207. 
KQ1E5b, KQ2E5b, KQ3E5b. 
125.  Tait RJ, Hulse GK, Robertson SI, et al. 
Emergency department-based intervention 
with adolescent substance users: 12-month 
outcomes. Drug Alcohol Depend 2005 Sep 
1;79(3):359-63. PMID: 16102378. 
KQ1E5b, KQ2E5b, KQ3E5b. 
126.  Vitaro F, Dobkin PL. Prevention of 
substance use/abuse in early adolescents 
with behavior problems. J Alcohol Drug 
Educ 1996;41(2):11-38. PMID: None. 
KQ1E2a, KQ2E2a, KQ3E2a. 
127.  Waldron HB, Slesnick N, Brody JL, et al. 
Treatment outcomes for adolescent 
substance abuse at 4- and 7-month 
assessments. J Consult Clin Psychol 2001 
Oct;69(5):802-13. PMID: 11680557. 
KQ1E5c, KQ2E5c, KQ3E5c. 
128.  Walker DD, Stephens R, Roffman R, et al. 
Randomized controlled trial of motivational 
enhancement therapy with nontreatment-
seeking adolescent cannabis users: a further 
test of the teen marijuana check-up. Psychol 
Addict Behav 2011 Sep;25(3):474-84. 
PMID: 21688877. KQ1E2a, KQ2E2a, 
KQ3E2a. 
129.  Walton MA, Bohnert K, Resko S, et al. 
Computer and therapist based brief 
interventions among cannabis-using 
adolescents presenting to primary care: One 
year outcomes. Drug Alcohol Depend 2013 
May 24 PMID: 23711998. KQ3E4. 
Drug Misuse in Children and Adolescents 67  Kaiser Permanente Research Affiliates EPC 
Appendix B. Excluded Studies 
130.  Wechsberg WM, Novak SP, Zule WA, et al. 
Sustainability of intervention effects of an 
evidence-based HIV prevention intervention 
for African American women who smoke 
crack cocaine. Drug Alcohol Depend 2010 
Jun 1;109(1-3):205-12. PMID: 20219294. 
KQ1E5a, KQ2E5a, KQ3E5a. 
131.  Weiss FL, Nicholson HJ. Friendly 
PEERsuasion against substance use: The 
Girls Incorporated model and evaluation. 
Drugs Soc 1998;12(1-2):7-22. PMID: None. 
KQ1E4, KQ2E4, KQ3E4. 
132.  Werch CC, Moore MJ, DiClemente CC, et 
al. A multihealth behavior intervention 
integrating physical activity and substance 
use prevention for adolescents. Prev Sci 
2005 Sep;6(3):213-26. PMID: 16133900. 
KQ1E2a, KQ2E2a, KQ3E2a. 
133.  Werch CE, Moore MM, DiClemente CC, et 
al. Single vs. multiple drug prevention: is 
more always better?: a pilot study. Subst 
Use Misuse 2005;40(8):1085-101. PMID: 
16040370. KQ1E2a, KQ2E2a, KQ3E2a. 
134.  Werch CE, Moore MJ, Bian H, et al. 
Efficacy of a brief image-based multiple-
behavior intervention for college students. 
Ann Behav Med 2008 Oct;36(2):149-57. 
PMID: 18800217. KQ1E2a, KQ2E2a, 
KQ3E2a. 
135.  Werch CE, Bian H, Moore MJ, et al. Brief 
multiple behavior health interventions for 
older adolescents. Am J Health Promot 2008 
Nov;23(2):92-6. PMID: 19004157. 
KQ1E2a, KQ2E2a, KQ3E2a. 
136.  Whicher EV, Utku F, Schirmer G, et al. 
Pilot project to evaluate the effectiveness 
and acceptability of single-session brief 
counseling for the prevention of substance 
misuse in pregnant adolescents. Addict 
Disord Their Treat 2012;11(1):43-9. PMID: 
None. KQ1E8, KQ2E8, KQ3E8. 
137.  Wiggins M, Bonell C, Sawtell M, et al. 
Health outcomes of youth development 
programme in England: prospective matched 
comparison study. BMJ 2009;339:b2534. 
PMID: 19584408. KQ1E7a, KQ2E7a, 
KQ3E7a. 
138.  Williams C, Griffin KW, Macaulay AP, et 
al. Efficacy of a drug prevention CD-ROM 
intervention for adolescents. Subst Use 
Misuse 2005;40(6):869-78. PMID: 
15974146. KQ1E9, KQ2E9, KQ3E9. 
139.  Winters K. Brief intervention for drug-
abusing adolescents. Proceedings of the 70th 
Annual Scientific Meeting of the College on 
Problems of Drug Dependence.  2008 Jun 
14; San Juan, Puerto Rico. 2008. p. 204. 
PMID: None. KQ1E2a, KQ2E2a, 
KQ3E2a. 
140.  Winters KC, Leitten W. Brief intervention 
for drug-abusing adolescents in a school 
setting. Psychol Addict Behav 2007 
Jun;21(2):249-54. PMID: 17563146. 
KQ1E2a, KQ2E2a, KQ3E2a. 
141.  Wolchik SA, Sandler IN, Millsap RE, et al. 
Six-year follow-up of preventive 
interventions for children of divorce: a 
randomized controlled trial. JAMA 2002 
Oct 16;288(15):1874-81. PMID: 12377086. 
KQ1E2b, KQ2E2b, KQ3E2b. 
142.  Wolchik SA, Millsap RE. Group based 
interventions for mothers and mothers plus 
children reduced mental health problems in 
adolescent children of divorced parents. 
Evid Based Nurs 2003;6(3):74. PMID: 
12882187. KQ1E2b, KQ2E2b, KQ3E2b. 
143.  Zahradnik A, Otto C, Crackau B, et al. 
Randomized controlled trial of a brief 
intervention for problematic prescription 
drug use in non-treatment-seeking patients. 
Addiction 2009 Jan;104(1):109-17. PMID: 
19133895. KQ1E5a, KQ2E5a, KQ3E5a. 
144.  Zonnevylle-Bender MJ, Matthys W, van de 
Wiel NM, et al. Preventive effects of 
treatment of disruptive behavior disorder in 
middle childhood on substance use and 
delinquent behavior. J Amer Acad Child 
Adolesc Psychiatry 2007 Jan;46(1):33-9. 
PMID: 17195727. KQ1E7a, KQ2E7a, 
KQ3E7a. 
 
Drug Misuse in Children and Adolescents 68  Kaiser Permanente Research Affiliates EPC 
Appendix C. Trials Pending Assessment 
Author Design Population Intervention(s) Comparator(s) Relevant outcomes Reported status 
Arnaud, 201274 
Germany 
RCT Adolescents ages 16 to 18 
years with a positive screen on 
the CRAFFT for risky substance 
use  
WISEteens Web-based screening 
and brief intervention 
No intervention Reductions in 
frequency and quantity 
of use of drugs, 
consumption per 
occasion 
Ongoing, 
estimated 
completion 2013 
Blow, 201275 
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RCT Adolescents ages 12 to 18 
years 
1) Brief motivational intervention by 
therapist 
2) Computerized brief motivational 
intervention 
Drug prevention 
booklet 
Marijuana use, other 
substance use, 
initiation of drug use 
Estimated 
completion 
November 2013 
Bukstein, 
201176 
United States 
RCT Adolescents ages 11 to 14 
years with a disruptive behavior 
diagnosis and using ≥1 
substances regularly 
Adolescent skills, parent 
management, parent-adolescent 
negotiation, home-based treatment 
Treatment as 
usual (for 
behavioral 
problems and 
substance use) 
Substance use Completed May 
2009, no 
publications 
Chaplin,  
201377 
United States  
RCT Parents of 12- to 14-year-olds 
reporting high parenting stress 
Parenting-focused, mindfulness-
based stress reduction 
Parent advice only Substance use Ongoing 
Collins, 201078 
United States 
RCT Rural Mexican American female 
adolescents ages 13 to 19 years 
Community-based cognitive 
behavioral intervention based on 
an AIDS risk reduction model, 
including individual and group 
sessions with support groups 
Enhanced 
counseling 
Substance use Ongoing 
Epton, 201379 
United 
Kingdom 
RCT Undergraduate student entering 
a university 
Online health behavior intervention, 
including self-affirmation, theory-
based message, and 
implementation intentions 
Control Recreational drug use Ongoing 
Hides,  201180 
Australia 
RCT Adolescents and young adults 
ages 16 to 25 years with a 
Kessler 10 score of ≥18 and 
weekly cannabis use 
Two sessions of brief motivational 
interviewing 
One session 
assessment 
feedback/ 
intervention  
Reduction in cannabis 
use 
Ongoing 
Knight, 201181 
United States 
RCT Adolescents ages 12 to 18 
years screened for substance 
use 
Internet-facilitated screening, brief 
intervention, and referral to 
treatment 
Treatment as 
usual 
Substance use Estimated 
completion, 
October 2016 
Knight, 201173 
United States 
RCT Adolescents and young adults 
ages 12 to 21 years 
1) Internet/intranet-based 
motivational enhancement therapy 
2) Internet/intranet-based 
motivational enhancement therapy 
+ technological extenders 
Treatment as 
usual 
Substance use, 
initiation and cessation 
of substance use 
Completed 
September 2011, 
no publications 
Knight, 201182 
United States 
RCT Adolescents and young adults 
ages 12 to 21 years who used 
alcohol, marijuana, or other 
drugs in the last 3 months 
Brief motivational enhancement 
therapy  
Enhanced 
standard care 
Substance use, driving 
or riding while under 
the influence of 
substances, 
substance-related risk 
behaviors 
Completed May 
2010, no 
publications 
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Laporte, 2012 
United States 
RCT French adolescents and young 
adults ages 15 to 25 years who 
are repeat or regular users of 
cannabis 
Brief intervention for cannabis use Control (details 
NR) 
Marijuana use Estimated 
completion, March 
2014 
Levy, 201283 
United States 
RCT Adolescents ages 14 to 18 years 
with a chronic medical condition 
(e.g., diabetes, asthma, 
ulcerative colitis, rheumatologic 
disorder) 
Brief motivational intervention 
aimed at encouraging the 
participant to decrease substance 
use 
Treatment as 
usual (brief health 
education 
brochure) 
Days abstinent from 
substance use 
Estimated 
completion, 
December 2014 
Lewis, 201284 
Australia 
RCT Adolescents and young adults 
ages 16 to 25 years diagnosed 
with anxiety or depression and 
substance misuse 
BEST Plus, SHADEY or SHADEY 
and BEST Plus cognitive therapy, 
and family education 
Waitlist control 
and those who 
refused to 
participate 
Adolescent Substance 
Abuse Subtle 
Screening Inventory 
Score 
Ongoing 
Metzler, 201385 
United States 
RCT Families of 3- to 8-year-olds 
with elevated behavior problems  
Internet-based Triple P Positive 
Parenting Program 
Usual community 
services/waitlist 
control 
Substance abuse Ongoing 
Mericle, 201286 
United States 
RCT Adolescents ages 12 to 18 
years 
1) Computer-assisted screening 
and brief advice 
2) Computer-assisted screening 
and brief advice + motivational 
enhancement therapy 
Treatment as 
usual 
Substance use Estimated 
completion, 
February 2016 
Shaw, 201287 
United States 
RCT Families of children ages 2 to 4 
years 
Family-centered early intervention NR Reductions in 
substance use risk from 
ages 2 to 10 years 
Ongoing 
Skeer, 201388 
United States 
RCT Parents and guardians of 
preadolescents ages 9 to 12 
years 
Brief, sex-specific substance use 
and misuse prevention intervention 
Control Intentions of use of 
substances, attitudes 
and expectancies 
regarding substance 
use 
Ongoing 
Spirito, 201289 
United States 
RCT Preadolescent children with a 
history of emotional/behavioral 
problems and their families 
Individually-tailored family program 
utilizing principles of motivational 
interviewing 
Standard care Marijuana use Completed March 
2011, no 
publications 
Van Hook, 
201371,72 
United States 
RCT Patients coming to primary care 
office 
VYou: computerized motivational 
enhancement therapy tool with 8 
interactive exercises 
NR Substance use Trial not yet 
conducted, 
awaiting funding 
Walker, 201090 
United States 
RCT Adolescents ages 14 to 19 
years who use marijuana 
Motivational enhancement 
treatment with optional skills 
training 
Educational 
feedback 
Marijuana use Estimated 
completion, 
September 2014 
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